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Abstract 
Abstract 
Medicinal Inorganic Chemistry is an area of growing interest owing to the fact that 
inorganic pharmaceuticals play a key role in clinical therapy (e.g; cisplatin and second 
generation alternatives carboplatin and oxaliplatin - chemotherapeutic agents for solid 
malignancies) and diagnostics (e.g; MR! contrast agents). For these inorganic 
compounds, the metal serves as structural center for organizing the organic ligands in the 
biologically relevant chemical space. Transition metals appear more appealing for this 
purpose because they can support a multitude of coordination numbers and geometries 
that go far beyond sp, sp^ and sp^ hybridization of carbon. The other key aspects for using 
metal containing compounds as structural scaffolds are; the kinetic stability of the 
coordination sphere in the biological environment, the stablization of certain or unusual 
ligand geometries, acquired redox activity, enhanced cellular uptake, different modes of 
action and synergistic effect from metal ion and ligands. 
Ligands can modify the deleterious effects of metal ion overload, inhibit selected 
metalloenzymes or facilitate systemic bioavailability of metal ions and can assist in 
targeting specific tissues or enzymes. Some important ligand modifying effects include 
modifying the reactivity, lipophilicity, stabilizing specific oxidation states and 
contributing to substitution inertness. Biological systems themselves provide numerous 
examples of designer ligands such as metalloprotein haemoglobin, manganese superoxide 
dismutase (MnSOD) and catalase. 
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Since DNA has been identified as the primary molecular target of metal based anticancer 
drugs, interaction of well tailored metal complexes with DNA ascertains the extent and 
mode of DNA binding and the potential of these complexes to act as chemotherapeutic 
agents. There are various modes of DNA interaction—covalent, non-covalent, 
intercalation etc. DNA targeted metal based drugs which involve covalent binding to 
nucleobase moieties have shown low degree of selectivity. Recently, non-covalent DNA 
binding metal complexes particularly metallointercalators have received attention in the 
development of efficient anticancer drugs. Intercalation is well known to strongly 
influence the properties of the DNA and has been reported to as preliminary step in 
mutagenesis. The interaction of metal complexes with nucleobases and/or nucleotides is 
very well established, and is now known to be the basis of antitumor drug action. The 
metal complexes, which are favoured as effective drug candidates are molecules that; 
(i) damage DNA 
(ii) block DNA synthesis indirectly through inhibition of nucleic acid precursor 
biosynthesis 
(iii) disrupt hormonal stimulation of cell growth 
(iv) must recognize nucleic acid particularly in sequence specific fashion and then bind to 
DNA in a way that alters their function. 
Recent advances in ligand design for metal-based drugs reveal that the ligand 
modifications in geometry, size, hydrophobicity, planarity, charge and hydrogen bonding 
I l l 
of the complexes, lead to spectacular changes in binding modes, location, affinity and to 
a different cleavage effect. 
Macrocycles form a major class of ligand molecules that encompasses a wide range of 
structure and functional groups. Their structures can be easily manipulated allowing the 
preparation of a variety of ring sizes as well as the addition of different side chains 
producing different types of macrocyclic molecules suitable for specific uses. With these 
perspectives, we have synthesized and characterized a variety of macrocyclic transition 
metal complexes. The interaction of these complexes with CT DNA/5'GMP have been 
studied by various biophysical techniques. 
New water soluble Co(II), Ni(II) and Cu(II) complexes of 4,15-bis(2-hydroxyethyl)-
2,4,6,13,15,17- hexaazatricyclodocosane were synthesized and characterized by various 
techniques, viz. elemental analysis, conductivity measurements, infrared, electronic, ESI-
MS, ' H and '^ C NMR spectroscopy. Molar conductance measurements in aqueous 
solution showed that complexes are ionic in nature. On the basis of spectroscopic data, a 
square planar geometry was assigned to the complexes involving four N-atoms of the two 
cyclohexane moieties. Interaction studies of [C2oH42N602Co]Cl2 and [C20H42N6O2CU ]Cl2 
with CT DNA were carried using UV/Visible absorption spectroscopy, fluorescence 
spectrophotometry, cyclic voltammetry and viscosity measurements. Absorption spectral 
traces reveal 27.7% and 23.3 % hyperchromism for complexes [C2oH42N602Co]Cl2 and 
[C2oH42N602Cu]Cl2, respectively indicative of strong binding to CT DNA. These results 
were authenticated by fluorescence quenching experimer\ts and viscosity measurements. 
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The intrinsic binding constants Kb of [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 are 
2.94.10'* M"' and 2.71.10'* M"', respectively. Early transition metals show preference for 
06 position while later ones copper and cobalt prefer N7 position of DNA base guanine. 
To validate this hypothesis, interaction studies of copper (11) and cobalt (II) complexes 
were carried out with 5'GMP, which revealed electrostatic interactions are more favored 
alongwith hydrogen bonding than coordinate covalent interaction to N7 position of 
guanine. The stability of the complexes were investigated by UV/Vis and cyclic 
voltammetry. The UV/Vis spectra and the voltammograms of the complexes exhibited no 
change over a wide pH range, which suggested the robust nature of these complexes in 
solution. The electrochemical behaviour of complexes was studied in Tris-HCI/KCl 
buffer and displayed a quasireversible M'VM' redox couples. In presence of DNA the 
complexes exhibited a shift in the formal potential with a decrease in anodic and cathodic 
peak currents indicating the binding of complexes to CT DNA. 
Benzimidazoles are very useful subunits for the development of molecules of 
pharmaceutical or biological interest. The biological relevance of these heterocyclic 
aromatic building blocks is due to their structural similarity to purine nucleobases. New 
benzimidazole derived homodinuclear macrocyclic complexes of Cobalt(Il), Copper(II) 
and Zinc(ll) were isolated from the newly synthesized ligand 2,2,2',2'-S,S[bis(bis-N,N-2-
thiobenzimidazolyloxalato-l,2-ethane)]. The structures of the complexes were elucidated 
by elemental analysis, molar conductance measurements, IR, ' H N M R , '^C NMR, 
electronic and ESI MS spectroscopic techniques. In complex [C36H24N804S4Co2]Cl4, 
Co(ll) ions possess a tetrahedral coordination environment composed of O2S2 donor 
atoms while its Cu(II) and Zn(II) counterparts [C36H24N8O4S4CI4CU2] and 
[C36H24N804S4Cl4Zn2] respectively reveal a six coordinate octahedral structure, defined 
by the O2S2 donors from the macrocyclic ring and two chloride ions. Molar conductance 
and spectroscopic data also support the proposed geometry of the complexes. DNA 
binding properties of complexes [C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and 
[C36H24N804S4Cl4Zn2] Were investigated using electronic absorption spectroscopy, 
fluorescence spectroscopy, viscosity measurements and cyclic voltammetry. The 
absorption spectra of the complexes [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] 
with calf thymus DNA showed hypochromism, while complex [C36H24N804S4Co2]Cl4 
showed hyperchromism attributed to a partial intercalation and electrostatic binding 
modes respectively. The intrinsic binding constant Kb of complexes 
[C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] were 
determined as 16.6 . 10'* M"', 4.25 . 10'* M"' and 3.0 . 10'* M"', respectively. The decrease 
in the relative specific viscosity of calf thymus DNA with increasing concentration of the 
complexes authenticates the partial intercalation binding mode. Gel electrophoresis of 
complex [C36H24N8O4S4CI4CU2] with pBR322 plasmid DNA demonstrated that complex 
exhibits excellent "artificial" nuclease activity via an oxidative cleavage pathway. 
Homonuclear bis-macrocyclic complexes where the two metal ions act in unison may 
bind much more tightly than the corresponding monometallic complexes through a 
concerted two point DNA binding mechanism. A new series of bis-macrocyclic 
VI 
complexes of Co(II), Ni(II) and Cu(II) containing pyridyl bridges between 13-membered 
macrocyclic subunits have been synthesized via in situ one pot template condensation 
reaction (lOPTCR). The proposed structures of these new dinuclear complexes are 
consistent with the data obtained from elemental analysis, molar conductance, IR, EPR, 
UV/Vis, ESI-MS, ' H and '^ C spectroscopy. The complexes have square planar geometry 
with four secondary nitrogen atoms coordinated to the metal ion. DNA binding properties 
of the complexes [C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4 were investigated 
by absorption and emission titrations; cyclic voltammetry and viscosity measurements. 
Complexes [C2iH43NiiCo2](C104)4 and [C2iH43Ni|Cu2](C104)4 are avid DNA binders 
with binding constants K^  1.64 x 10^  and 2.05 x 10 ,^ respectively. Hyperchromism, 
decrease in emission intensity of DNA bound EthBr and changes observed in the 
viscosity and cyclic voltammograms in presence of added metal complexes reveals that 
the complexes bind to DNA predominantly by electrostatic attraction, substantiated by 
absorption titration with 5'GMP. No shifts in the visible absorption bands were observed 
which implies that there is no change of the coordination environment of the metal ions. 
These results reveal that the complexes interact with 5'GMP exclusively through 
hydrogen bonding of-NH- groups to base nitrogen atom or phosphate oxygen atom or by 
electrostatic interactions of the metal ions utilizing the phosphate oxygen atoms of the 
nucleotide. The quenching of EthBr bound to DNA by the metal complex is in good 
agreement with the linear Stern-Volmer equation. 
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Functionalized pyran-2-ones are key structural motifs found in a large number of 
biologically important natural products. In this context, another series of new 
macrocyclic Co(II), Ni(II), Cu(II) and Zn(II) complexes were synthesized by schiff base 
condensation reaction of 1,2-diaminocyclohexane and the P-diketonate functionalized 
coumarin ligand 3-acetoacetyl-7-methyl -pyrano-(4,3-b)-pyran-2,5-dione. The formation 
of the ligand and the complexes was ascertained from elemental analysis, IR, 'H N M R , 
C NMR, UV/Vis and mass spectroscopies. Molar conductance and spectroscopic data 
reveal an octahedral geometry of the complexes around the metal ions. In vitro DNA 
binding studies of the ligand and the C3gH44N40i8Cl2 complex were investigated by 
electronic absorption and fluorescence titrations. The ligand exhibited hyperchromism 
due to the aggregation of the planar ligand molecule on the DNA surface. The complex 
shows hypochromism in the UV region and the hyperchromism at the d-d absorption 
bands, which suggests that the complex has intimate association with CT DNA and binds 
to helix via partial intercalation and simultaneously increases the probability for 
electrostatic association due to the strong Lewis acid copper center. The binding 
constants K^  for the ligand and the complexes are 3.2.10^ M"' and 2.18 .10^ M" 
respectively. To identify the specific binding mode, absorption titration of 
C38H44N40,8Cl2 complcx with 5'GMP were performed. Hyperchromism at the UV 
absorption bands and no change at the d-d absorption bands supported a non-covalent 
binding mode. This was also confirmed by NMR studies of the complex with 5'GMP. 
The intrinsic binding constants were also estimated from emission titrations using 
VIII 
Scatchard equation and were found to be 3.0 .10'* M''and 2.0 .lO"* M"' for the ligand and 
the complex, respectively. The metal complex also cleaved pBR322 plasmid DNA by an 
oxidative cleavage mechanism in presence of ascorbic acid as the reducing agent. In vitro 
cytotoxicity of the ligand was determined against different human cancer cell lines using 
standard protocols. The highest growth inhibitory effect was observed for CNS cancer 
SNB-75 cell lines. 
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Medicinal Inorganic Chemistry is an area of growing interest owing to the fact that 
inorganic pharmaceuticals play a key role in clinical therapy (e.g; cisplatin and second 
generation alternatives carboplatin and oxaliplatin - chemotherapeutic agents for solid 
malignancies) and diagnostics (e.g; MRI contrast agents). For these inorganic 
compounds, the metal serves as structural center for organizing the organic ligands in the 
biologically relevant chemical space. Transition metals appear more appealing for this 
purpose because they can support a multitude of coordination numbers and geometries 
that go far beyond sp, sp^ and sp^ hybridization of carbon. The other key aspects for using 
metal containing compounds as structural scaffolds are; the kinetic stability of the 
coordination sphere in the biological environment, the stablization of certain or unusual 
ligand geometries, acquired redox activity, enhanced cellular uptake, different modes of 
action and synergistic effect from metal ion and ligands. 
Ligands can modify the deleterious effects of metal ion overload, inhibit selected 
metalloenzymes or facilitate systemic bioavailability of metal ions and can assist in 
targeting specific tissues or enzymes. Some important ligand modifying effects include 
modifying the reactivity, lipophilicity, stabilizing specific oxidation states and 
contributing to substitution inertness. Biological systems themselves provide numerous 
examples of designer ligands such as metal loprotein haemoglobin, manganese superoxide 
dismutase (MnSOD) and catalase. 
Since DNA has been identified as the primary molecular target of metal based anticancer 
drugs, interaction of well tailored metal complexes with DNA ascertains the extent and 
mode of DNA binding and the potential of these complexes to act as chemotherapeutic 
agents. There are various modes of DNA interaction—covalent, non-covalent, 
intercalation etc. DNA targeted metal based drugs which involve covalent binding to 
nucleobase moieties have shown low degree of selectivity. Recently, non-covalent DNA 
binding metal complexes particularly metallointercalators have received attention in the 
development of efficient anticancer drugs. Intercalation is well known to strongly 
influence the properties of the DNA and has been reported to as preliminary step in 
mutagenesis. The interaction of metal complexes with nucleobases and/or nucleotides is 
very well established, and is now known to be the basis of antitumor drug action. The 
metal complexes, which are favoured as effective drug candidates are molecules that; 
(i) damage DNA 
(ii) block DNA synthesis indirectly through inhibition of nucleic acid precursor 
biosynthesis 
(iii) disrupt hormonal stimulation of cell growth 
(iv) must recognize nucleic acid particularly in sequence specific fashion and then bind to 
DNA in a way that alters their function. 
Recent advances in ligand design for metal-based drugs reveal that the ligand 
modifications in geometry, size, hydrophobicity, planarity, charge and hydrogen bonding 
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of the complexes, lead to spectacular changes in binding modes, location, affinity and to 
a different cleavage effect. 
Macrocycles form a major class of ligand molecules that encompasses a wide range of 
structure and functional groups. Their structures can be easily manipulated allowing the 
preparation of a variety of ring sizes as well as the addition of different side chains 
producing different types of macrocyclic molecules suitable for specific uses. With these 
perspectives, we have synthesized and characterized a variety of macrocyclic transition 
metal complexes. The interaction of these complexes with CT DNA/5'GMP have been 
studied by various biophysical techniques. 
New water soluble Co(ll), Ni(II) and Cu(ll) complexes of 4,15-bis(2-hydroxyethyl)-
2,4,6,13,15,17- hexaazatricyclodocosane were synthesized and characterized by various 
techniques, viz. elemental analysis, conductivity measurements, infrared, electronic, ESI-
MS, H and C NMR spectroscopy. Molar conductance measurements in aqueous 
solution showed that complexes are ionic in nature. On the basis of spectroscopic data, a 
square planar geometry was assigned to the complexes involving four N-atoms of the two 
cyclohexane moieties. Interaction studies of [C2oH42N602Co]Cl2 and [C20H42N6O2CU ]Cl2 
with CT DNA were carried using UV/Visible absorption spectroscopy, fluorescence 
spectrophotometry, cyclic voltammetry and viscosity measurements. Absorption spectral 
traces reveal 27.7% and 23.3 % hyperchromism for complexes [C2oH42N602Co]Cl2 and 
[C2oH42N602Cu]Cl2, respectively indicative of strong binding to CT DNA. These results 
were authenticated by fluorescence quenching experiments and viscosity measurements. 
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The intrinsic binding constants Kb of [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 are 
2.94.10'' M"' and 2.71.10'* M'', respectively. Early transition metals show preference for 
06 position while later ones copper and cobalt prefer N7 position of DNA base guanine. 
To validate this hypothesis, interaction studies of copper (II) and cobalt (II) complexes 
were carried out with 5'GMP, which revealed electrostatic interactions are more favored 
alongwith hydrogen bonding than coordinate covalent interaction to N7 position of 
guanine. The stability of the complexes were investigated by UV/Vis and cyclic 
voltammetry. The UV/Vis spectra and the voltammograms of the complexes exhibited no 
change over a wide pH range, which suggested the robust nature of these complexes in 
solution. The electrochemical behaviour of complexes was studied in Tris-HCl/KCl 
buffer and displayed a quasireversible M'VM' redox couples. In presence of DNA the 
complexes exhibited a shift in the formal potential with a decrease in anodic and cathodic 
peak currents indicating the binding of complexes to CT DNA. 
Benzimidazoles are very useful subunits for the development of molecules of 
pharmaceutical or biological interest. The biological relevance of these heterocyclic 
aromatic building blocks is due to their structural similarity to purine nucleobases. New 
benzimidazole derived homodinuclear macrocyclic complexes of Cobalt(II), Copper(II) 
and Zinc(II) were isolated from the newly synthesized ligand 2,2,2',2'-S,S[bis(bis-N,N-2-
thiobenzimidazolyloxalato-l,2-ethane)]. The structures of the complexes were elucidated 
by elemental analysis, molar conductance measurements, IR, 'H N M R , '^C NMR, 
electronic and ESI MS spectroscopic techniques. In complex [C36H24N804S4Co2]Cl4, 
Co(II) ions possess a tetrahedral coordination environment composed of O2S2 donor 
atoms while its Cu(II) and Zn(II) counterparts [C36H24N8O4S4CI4CU2] and 
[C36H24N804S4Cl4Zn2] respectively reveal a six coordinate octahedral structure, defined 
by the O2S2 donors from the macrocyclic ring and two chloride ions. Molar conductance 
and spectroscopic data also support the proposed geometry of the complexes. DNA 
binding properties of complexes [C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and 
[C36H24N804S4Cl4Zn2] wcrc investigated using electronic absorption spectroscopy, 
fluorescence spectroscopy, viscosity measurements and cyclic voltammetry. The 
absorption spectra of the complexes [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] 
with calf thymus DNA showed hypochromism, while complex [C36H24N804S4Co2]Cl4 
showed hyperchromism attributed to a partial intercalation and electrostatic binding 
modes respectively. The intrinsic binding constant Kb of complexes 
[C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] were 
determined as 16.6 . 10'*M"', 4.25 . lO'^M'' and 3.0 . lO'^ M"', respectively. The decrease 
in the relative specific viscosity of calf thymus DNA with increasing concentration of the 
complexes authenticates the partial intercalation binding mode. Gel electrophoresis of 
complex [C36H24N8O4S4CI4CU2] with pBR322 plasmid DNA demonstrated that complex 
exhibits excellent "artificial" nuclease activity via an oxidative cleavage pathway. 
Homonuclear bis-macrocyclic complexes where the two metal ions act in unison may 
bind much more tightly than the corresponding monometallic complexes through a 
concerted two point DNA binding mechanism. A new series of bis-macrocyclic 
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complexes of Co(Il), Ni(II) and Cu(II) containing pyridyl bridges between 13-membered 
macrocyclic subunits have been synthesized via in situ one pot template condensation 
reaction (lOPTCR). The proposed structures of these new dinuclear complexes are 
consistent with the data obtained from elemental analysis, molar conductance, IR, EPR, 
UV/Vis, ESI-MS, 'H and '^ C spectroscopy. The complexes have square planar geometry 
with four secondary nitrogen atoms coordinated to the metal ion. DNA binding properties 
of the complexes [C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4 were investigated 
by absorption and emission titrations; cyclic voltammetry and viscosity measurements. 
Complexes [C2iH43N|iCo2](C104)4 and [C2iH43NiiCu2](C104)4 are avid DNA binders 
with binding constants K/, 1.64 x 10^  and 2.05 x 10 ,^ respectively. Hyperchromism, 
decrease in emission intensity of DNA bound EthBr and changes observed in the 
viscosity and cyclic voltammograms in presence of added metal complexes reveals that 
the complexes bind to DNA predominantly by electrostatic attraction, substantiated by 
absorption titration with 5'GMP. No shifts in the visible absorption bands were observed 
which implies that there is no change of the coordination environment of the metal ions. 
These results reveal that the complexes interact with 5'GMP exclusively through 
hydrogen bonding of-NH- groups to base nitrogen atom or phosphate oxygen atom or by 
electrostatic interactions of the metal ions utilizing the phosphate oxygen atoms of the 
nucleotide. The quenching of EthBr bound to DNA by the metal complex is in good 
agreement with the linear Stern-Volmer equation. 
vu 
Functionalized pyran-2-ones are key structural motifs found in a large number of 
biologically important natural products. In this context, another series of new 
macrocyclic Co(II), Ni(II), Cu(II) and Zn(II) complexes were synthesized by schiff base 
condensation reaction of 1,2-diaminocyclohexane and the P-diketonate functionalized 
coumarin ligand 3-acetoacetyl-7-methyl -pyrano-(4,3-b)-pyran-2,5-dione. The formation 
of the ligand and the complexes was ascertained from elemental analysis, IR, 'H N M R , 
'^ C NMR, UV/Vis and mass spectroscopies. Molar conductance and spectroscopic data 
reveal an octahedral geometry of the complexes around the metal ions. In vitro DNA 
binding studies of the ligand and the C38H44N4O18CI2 complex were investigated by 
electronic absorption and fluorescence titrations. The ligand exhibited hyperchromism 
due to the aggregation of the planar ligand molecule on the DNA surface. The complex 
shows hypochromism in the UV region and the hyperchromism at the d-d absorption 
bands, which suggests that the complex has intimate association with CT DNA and binds 
to helix via partial intercalation and simultaneously increases the probability for 
electrostatic association due to the strong Lewis acid copper center. The binding 
constants K* for the ligand and the complexes are 3.2.10^ M"' and 2.18 .10^ M"' 
respectively. To identify the specific binding mode, absorption titration of 
C38H44N4O18CI2 complex with 5'GMP were performed. Hyperchromism at the UV 
absorption bands and no change at the d-d absorption bands supported a non-covalent 
binding mode. This was also confirmed by NMR studies of the complex with 5'GMP. 
The intrinsic binding constants were also estimated from emission titrations using 
Vlll 
Scatchard equation and were found to be 3.0 .10'* M''and 2.0 .lO"* M"' for the ligand and 
the complex, respectively. The metal complex also cleaved pBR322 plasmid DNA by an 
oxidative cleavage mechanism in presence of ascorbic acid as the reducing agent. In vitro 
cytotoxicity of the ligand was determined against different human cancer cell lines using 
standard protocols. The highest growth inhibitory effect was observed for CNS cancer 
SNB-75 cell lines. 
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CHAPTER I 
Introduction 
Introduction 
Medicinal Inorganic Chemistry is an interdisciplinary area of growing interest, which 
offers exciting possibilities for the design of novel metal-based therapeutic 
agents/diagnostic agents with unique mechanisms of action [1-8]. Undoubtedly, the well 
recognized success of Bamett Rosenberg in 1960 with the discovery of cisplatin [cis-
(PtCl2(NH3)2)] as the first archetypical inorganic anticancer drug opened new vistas in the 
frontier areas of research in chemical and biological sciences [9-12]. The success of 
cisplatin has aroused great interest in the development of new innovative metal 
complexes - 'classic' platinum based, non-classic platinum-based (as they did not mimic 
cisplatin in their modes of action) and non-platinum metal complexes [13,14]. Hitherto, 
thousands of complexes in last four decades have been synthesized and investigated in 
vitro and in vivo for active therapeutic profile to treat diseases including Aids HIV, 
Alzheimer's, cancer and diabetes [15,16]. Amongst the noteworthy are: AMD3100, 
Mozobil- a potent anti HIV agent [17], NAMI-A and KP1019-rutheniimi anficancer 
agents [18-20], BMOV- Bis(maltolatooxovanadium IV) the first purpose designed 
vanadium based insulin enhancing antidiabetic agent [21-23] (Figure 1). Non-platinum 
class of metal-based chemotherapeutics possess preconditions viz; differences in 
coordination geometry, binding preferences according to the HSAB, hard and soft acids 
and bases principle (late transition metal divalent ions show preference to N7 and 06 
atoms of guanine, which were considered as borderline Pearson bases; hard acids prefer 
hard bases and so on), electrovalency and redox activity and icinetics of ligand exchange 
reactions or even the replacement of essential metals [24]. 
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Figure 1. Structures of chemotherapeutic metal-based agents (a) AMD3100 (b) BMOV 
(c) NAMI-A and (d) KP1019. 
These preconditions form the chemical basis for a diversity of pharmacologically relevant 
interactions with biomolecules viz; molecular DNA and nucleotides. This has opened up 
a new field of nucleic acid—metal ion interaction that is contributing beyond traditional 
sciences, biotechnology, biochemistry, genetics, medicinal chemistry and others. Metal 
ions are essential for charge compensation of the negatively charged phosphate sugar 
backbone [25-27]. They are instrumental for proper folding, and are crucial cofactors for 
ribozyme catalysis [28,29]. The design of strategy for synthesis of the metal-based drugs 
employs well-tailored multifunctional biologically active ligands [30-32]. The reactivity 
of the metal is subordinate to the activity of the ligands; the metal ions rather serve to 
modulate/tune this activity and achieve specific molecular recognition with a defined 
target thereby limiting drug toxicity. Metal complexation alters the solubility and 
lipophilicity of the drug resulting in changes in its pharmacokinetics, biodistribution and 
biotransformation [33]. Transition metals possess different oxidation states which not 
only allow for modification of the 3-dimensional space into which the molecule can fit 
but significantly allows them to participate in biological redox chemistry [34]. In 
addition, the ability to undergo ligand exchange reactions offer opportunities for metals 
to interact and coordinate with nucleobases of molecular target DNA [35]. By optimizing 
choice of ligands and oxidation state, kinetics and thermodynamic properties of 
metallopharmoceuticals can be exploited for specific therapeutic requirements [36]. 
To design a metal- based applicable anticancer drug, macrocyclic ligands hold promise as 
they are rigid enough to provide metal binding sites and orient functional groups 
stereoselectively, yet flexible enough to accommodate structural changes required for 
induced fit recognition of biological targets [37]. Metallomacrocycles are of interest in 
fields as diverse as catalysis, selective metal recovery, sensors and therapy and diagnosis 
[38-43]. Saturated tetraazamacrocycles-l,4,7,10-tetraazacyclododecane (cyclam) and 
1,4,8,11- tetraazacyclododecane (cyclen) and their derivatives have been extensively 
studied for their antitumour and anti-HIV activity [44-46]. There is current medical 
interest in the drug AMDS 100, a bicyclam containing cyclam units connected by a p-
phenylene bis(methylene) (p-xylyl) linker. Mozobil AMD3100 is in phase (II) clinical 
trials for stem cell transplantation used in the treatment of patient who have cancers 
involving the blood and immune system [47]. It is also most potent anti-HIV agent 
known [48]. These cyclams are strong chelating agents. Complexation of AMDS 100 to 
Zn(II) enhances co-receptor binding strength and anti-HIV activity, whereas Pd(II) 
binding inactivates the drug. The order of activity is Zn(II)2 > AMDS 100 > Ni(ir) 2 > 
Cu(II) 2 » Co(II) 2 > » Pd(II) 2 [49]. 
BiTPC, a Bi(m) complex of TPC (1,4,7,10-tetrakis(2-pyridylmethyl)-1,4,7,10-
tetraazacyclododecane exhibited a very high cytotoxic activity against melanoma B16-
BLC cells [50]. The IC50 of BiTPC is 4.1x10* M, which was 100 times more potent than 
the cisplatin. Stable Au(III) complex of 1,4,7-tetrazacyclododecane is known to induce 
distortions of DNA double helix [51] and was foimd to be more cytotoxic than cisplatin 
against A-549 and HCT-116 cell lines (Figure 2). 
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Figure 2. Structures of TPC (left) andAuTACN (right). 
A characteristic feature of many malignant cancers is the rapid, and unregulated growth 
of cell populations. These cells also typically possess genetic instability, predisposing 
them to develop resistance to chemotherapeutic agents [52,53]. During cancer 
chemotherapy, after single agent treatment, a resistance subpopulation of cells is often 
seen to survive. To circumvent this resistance for effective clinical treatment, a co-
administration of a combination of at least two drugs is administered simultaneously or 
sequentially to inhibit tumour growth [54]. This approach although successful leads to 
toxicity problems and therefore to reduce non-tumour cell toxicity chemotherapeutic 
agents with specific target location are being developed [55-57]. Towards this approach, 
two biologically significant moieties are tethered in combination and thereby referred as 
'conjugates' to yield a more efficacious, less toxic chemotherapeutic drug. Darren Magda 
et al have synthesized a conjugate of motexafm gadolinium MGd and an experimental 
drug demonstrating significant tumours targeting with a porphyrin methotrexate 
(Matrex® trade name) MTX N-[4-[[(2,4-diamino-6-
pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid -a DNA synthesis inhibitor 
[58] (Figure 3). The resulting conjugates exhibited greater activity than the corresponding 
amide conjugate or methotrexate alone. In vivo tumour localization of the conjugates is 
often correlated with higher molecular weight and more lipophilic molecules which 
extent circulation times and improves uptake of the conjugates [59,60]. This approach has 
facilitated the development of anticancer drugs with improved selectivity and 
bioavailablity where the macrocyclic core behaves as a 'pro-drug' that cleaves under 
physiological conditions. Currently, MGd is undergoing clinical trials for a range of 
cancer indications [61,62]. MGd, which is MRI detectable, has been extensively studied 
in combination with X-ray radiation therapy (XRT) or as a direct chemotherapeutic agent 
either alone or in conjunction with other anticancer agents [63,64]. 
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Figure 3. Synthesis of ester conjugate from MGd and MTX. 
Polyaza macrocyclic ligands and complexes bearing additional functional pendant arms, 
such as aminoalkyl, hydroxyalkyl, carboxylic acid, amide and carboxylic esters have 
received much attention owing to their interesting chemical properties and potential 
applications in various fields [65-72]. It has been demonstrated that introduction of 
additional functional groups into polyaza macrocylic compounds causes a considerable 
change into chemical and biological properties [73,74]. Since the properties of the 
macrocyclic compounds are correlated with structural characteristic of the ligands, many 
efforts have been made to obtain new types of macrocyclic compounds, which are 
expected to exhibit specific properties [75]. Structural parameters, which can be varied, 
include the metal ions viz; size, degree of unsaturation and types and numbers of 
substituents on the macrocyclic rings. Shin-Goel Kang et al have synthesized a new 
macrocyclic ligand 3,14-dimethyl-2,6,13,17-tetraazatricyclo [16,4,0,0] docosa-2,12-diene 
that contains two cyclohexane rings at the macrocyclic backbone, by the non-template 
reaction of methyl vinyl ketone with 1,2-diaminocyclohexane [76]. Although a majority 
of macrocyclic ligands have beep prepared by metal ion template condensation of ketones 
and multiamines, some of them have also been obtained by non-template reactions 
[77,78]. 
Template directed synthesis is the organization of an assembly of atoms with respect to 
one or more geometric loci to achieve a particular linking of atoms [79,80]. It utilizes 
metal ions as the "anchor" of template complex. Lawrance et al used a Cu^ "^  template to 
produce ethylene side bridged 15-membered macrobicycles from piperazine derivatives 
[81]. The advantages of this template synthesis are the ease and high yield of the reaction 
as well as the addition of a pendant donor through reduction of a nitro group to amine 
(Figure 4). 
Ligands similar to those of Lawrance et al were produced by template reactions involving 
N,N'-bis[(CH2)n-NH2]-l,4-diazacycloheptanes as the starting materials in place of 
piperazine [82,83]. Besides, this topology is useful for designing therapeutic drugs since 
they provide unsaturated coordination environment and possess vacant coordination sites 
for binding/activation with substrate/drug target [84,85]. 
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Figure 4. Template closure of a side-bridged macrocycle. 
A highly efficient synthesis of carbamate polyazamacrocycles derived from chloroethyl 
pendant armed macrocycles was achieved by A. Sutherland et al [86]. These 
polyazamacrocycles were as cytotoxic as the well-known anticancer alkylating agents 
chlorambucil and melphalan and were known to exhibit significant biological acUvity 
(antiparasitic activity) owing to their pheirmacokinetic tunable substituents and reactive 
side chains [87] (Figure 5). Tuning the nature of these arms allows the creation of smart 
molecules with sp>ecific physical and chemical properties, which can be utilized for many 
applications in medicinal and analytical chemistry and NMR imaging. Polyamine 
mustards (derivatives of 1,4,7-triazacyclononane, 1,4,7,10-tetraazacyclododecane and 
1,4,8,11-tetraazacyclotetradecane) are candidates for conversion into hypoxia-selective 
prodrugs (an inactive form, which is metabolized in vivo to the active species) via 
complexation with metals [88]. The novel Cu(II) complexes of tacn, cyclen and cyclam 
were assessed in vitro as hypoxia-selective cytotoxins. Bioreductive drugs are prodrugs, 
which are selectively activated by intracellular reductases under hypoxic conditions. This 
is a consequence of an insufficient formation of new blood vessels in rapidly growing 
tumours and it is a major physiological difference between tumour and normal tissues 
[89]. The cylen mustard complex showed 24-fold selectivity as hypoxia selective 
bioreductive prodrug with an IC50 value of 2 (iM against lung tumour cell line A549 
(Figure 6). 
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Figure 5. Structures ofN-functionalized macrocyclic ligands. 
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Figure 6. Structures of Cu(II) complexes of N-Mustard derivatives of (a) Cyclen and 
(b)TACN 
A wide variety of linked macrocyclic ligands including species covalently linked by 
secondary species have been reported in an attempt to investigate metal ion recognition 
by such systems, including metal ion binding of mono-ring and xylyl-Iinked bis-ring 
systems [90,91]. Majority of these have involved polyamine rings although a number of 
mixed donor macrocyclic systems have also been investigated. Shim Sung Lee and 
Lindoy et al have synthesized NO2S2 donor macrocycle from the ring closure reaction 
between Boc-N-protected 2,2'-iminobis(ethanethiol) and 2,2'-(ethylenedioxy)bis(benzyl 
chloride) followed by deprotection of the Boc-group. a,a'-Dibromo-p-xylene was 
employed as a dialkylating agent to bridge two macrocyles to yield the corresponding N-
linked product [92]. Binuclear complexes of this N-linked macrocyle with heavy metals 
Hg(ll) and Cd(II) were also isolated (Figure 7). There is a growing interest in Cu(II) 
complexes of tetradentate bis(benzimidazol-2-yl)dithiother ligands as they offer N2S2 
chromophore in blue proteins [93]. Addison et al have studied Cu(ll) complexes of linear 
N2S3 ligands containing pyridyl, quinolyl and benzimidazolyl termini [94]. The structure 
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and properties of Cu(II) complexes of trithioether ligands containing substituted 
pyrazolyl [l,9-bis(3,5-dimethyl-l-pyrazolyl)-2,5,8-trithianonane,pzttn], benzimidazolyl 
[l,9-bis(3,5-benzimidazol-2-yl)-2,5,8-trithianonane, bzttn] and pyridyl [(l,9-bis(pyrid-2-
yl)-2,5,8-trithianonane, pttn] moieties were described [95,96]. S. Usha and M. 
Palanaindavar have described the effect of incorporating increasing number of sulphur 
donors and varying chelate ring size on the structure and spectra of Cu(II) complexes of 
bis(benzimidazol-2-yl)tetra- and penta-thioether ligands [97]. 
Figure 7. Xylyl-bridged ditopic NO2S2 donor macrocyle 
The study of these ligands provides an opportunity to gain insight into the relative 
importance of contributions from the coordination of thioethers and the benzimidazole 
which are readily accessible to the positive M(II)/M(I) redox potentials. In addition, 
imidazoles are common component of pharmacologically active molecules [98]. 
Benzimidazole group plays important role in several minor groove DNA binders such 
Hoechst 33258 and Hoechst 33342 and display wide range of biological activities 
including inhibition of DNA topoisomerase 1, antitumour and antiparasitic activities [99-
102]. These facts make imidazole and its derivatives important target analytes. 
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Deoxyribonucleic acid (DNA) is the primary cellular target molecule for most anticancer 
therapies [103]. Binding studies of small molecules with DNA are very important in the 
development of new therapeutic reagents and DNA molecular probes [104]. Nucleic 
acids under physiological conditions are polyanions composed of heterocyclic bases 
linked to a sugar-phosphate backbone. Thus, they are quite amenable to probe with 
positively charged transition metal ions. 
DNA is a flexible, dynamic and polymorphic in structure that can assume a variety of 
interconverting forms [105]. Each form has its own biological role in the regulation of the 
life of cell. Selective stabilization of one of these forms can help to discover and better 
imderstand their biological roles. Genetic information is provided by the DNA in at least 
two different ways. First, the sequence of its nucleotides determine the primary structure 
of the protein. Second, DNA can regulate gene expression through its shape [106]. 
Coordination compoimds offer many binding modes to polynucleotides, including outer 
sphere non-covalent binding, metal coordination to nucleobases and phosphate backbone 
sites, as well as strand cleavage induced by oxidation using redox-active metal centres 
(Figure 8). In covalent binding, the labile ligand of the complexes is replaced by a 
nitrogenous base of DNA such as guanine N7. On the other hand, the non-covalent DNA 
interactions include intercalation, electrostatic interaction, hydrogen bonding and groove 
(surface) binding of cationic metal complexes along outside of DNA helix, along major 
or minor groove. Intercalation involves the partial insertion of aromatic heterocyclic rings 
of ligands between the DNA base pairs [107]. 
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Figure 8. External binding (left), intercalation (middle), groove (right) binding 
Considerable progress was made in past few years on the identification of metal binding 
sites in large DNA molecules; however, to obtain information and to determine the 
coordination of a metal ion to a specific site, interaction with low-molecular building 
blocks of large nucleic acids viz mononuleotides and dinucleotides has become 
mandatory (Figure 9). Purine and pyrimidine nucleoside bases have been focus of many 
such studies. An excellent review article by Lippert has appeared a few years ago 
summarizing the multiplicity of behaviours known for most relevant purines (adenine, 
guanine and other 6-oxo purines) and pyrimidines [108]. It presents a series of general 
rules about different metal-nucleobase coordination modes with different metal ions. 
Similarly, Gutierrez et al have described structures of related copper(lI) complexes with 
purine nucleobase as a valuable source of information on molecular recognition patterns. 
The presence of amino or oxo group in C6 atom of adenine or guanine and its derivatives, 
respectively significantly increases their possibilities for developing a suitable 
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intramolecular inter ligand interactions that reinforces the corresponding Cu-N 
(nucleobase) coordination bond [109]. 
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Figure 9. Chemical structures of guanosine-5'monophosphate (5'-GMP^') and 
adenosine-5-monophosphate (5 '-AMP^') with atomic numbering. 
Relatively few studies have been focused on the potential of the DNA-binding ability of 
the macrocyclic complexes. However, Kimura and colleagues have described a series of 
macrocyclic complexes linked to intercalators and have shown that these interact with 
DNA in a sequence-selective manner [110-112]. On the basis of structure-activity 
correlation, sequence-specific DNA binding properties can be invoked by varying the 
substituents on the macrocyclic skeleton. Macrocycles are known to exhibit anticancer 
activity and a few- namely bryostatin have entered phase II human clinical trials for the 
treatment of melanoma, non-hodgkins lymphoma and renal cancers [113]. Bryostatins are 
a unique family of emerging cancer chemotherapeutic candidates isolated from marine 
bryozoa (Figure 10). An understanding of the structural basis for these bryostatin 
activities like high affinities for protein kinase PKC signal transduction is important for 
the development of simpler and clinically superior chemotherapeutic agents. Structure-
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activity relationships and related computer niodeling of bryostatins suggest that 
bryostatin binding is a cooperative event between two functional domains: one, the 
recognition domain containing elements that contact the receptor, and a second, a spacer 
which serves to properly orient and constraint the recognition domain. 
Figure 10. Structure of Bryostatin 
The numerous side effects of cisplatin as a chemotherapeutic agent leave room for the 
selection of other metals for the synthesis of bioactive molecules. Among these, Cu(II) 
ion is especially attractive due to its occurrence in biological systems and participation as 
an integral part of the active site of different types of metalloproteins, which recognize its 
coordination with the human body fimctions [114-116]. The exploration of copper 
complexes as chemical nucleases is well documented [117-123] because they possess 
biological accessible redox potential and relatively high nucleobase affinity [124,125] 
and are therefore selective at the molecular target site. Besides this, the tuning and 
prediction of redox potentials by structure modification provides a rational strategy for 
the development of tumour selective bioreductive drugs. 
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The macrocyclic copper (II) complexes of the formula [Cu(L')]Cl2, [Cu(L^)]Cl2, 
[Cu(L^)]Cl2, [Cu(L^)]Cl2 and [Cu(L^)](C 104)2 where (L ' = 3,10-bis(2-methylpyridine)-
1,3,5,8,10,12-hexaazacyclotetradecane, L^  = 3,10-bis(2-propionitrile)-l,3,5,8,10,12 
hexaazacyclotetra- decane, L^  = 3,10-bis(2-hydroxyethyl)-l,3,5,8,10,12 
hexaazacyclotetradecane, L'' = 3,10-bis(2-benzyl)-l,3,5,8,10,13-hexaazacyclotetradecane 
and L^  = 2,6,9,13-tetraparacyclophane) (Figure 11) interacted with DNA in different 
binding modes and exhibited effective nuclease activities [126,127]. The functional 
groups on the side chain of macrocycles play a key role in deciding the mode and extent 
of binding of Cu complexes to DNA. Therefore, extensive studies using different 
structural macrocycles to evaluate and understand the factors that determine mode and 
mechanism of the binding interaction of macrocyclic transition metal complexes with 
DNA are necessary. Absorption and fluorescence spectroscopic studies, cyclic 
voltammetry and viscosity measurements were used for the interaction of these 
macrocycles with CT DNA. 
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Figure 11. Chemical structures of the macrocyclic copper (II) complexes 
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The complex [Cu(L )^]Cl2 exhibits an increase in molar absorptivity (hyperchromism) 
with no shift. On addition of CT DNA, all the macrocyclic complexes except [Cu(L )^] 
CI2 show decrease in molar absorptivity (hypochromism) of the LMCT absorption band 
as well as red shift (Figure 12). 
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Figure 12. Absorption spectra of (a) fCul'jCh (b) fCuL^JCh (c) fCuL^JCh in the 
absence (...) and presence (- ) of increasing amounts of DNA 
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These observations suggest that copper complexes of L ' , L"* and L* ligands bind to DNA 
through partial intercalation by providing an aromatic moiety present in the side chain 
attached to macrocycle or within the macrocycle to overlap with the stacking base pairs 
of DNA helix. On the other hand, complexes [Cu(L^)]Cl2 and [Cu(L^)]Cl2 lack any fused 
aromatic ring to facilitate intercalation rather they possess -NH and -OH groups, which 
form hydrogen bonding with the base pairs of DNA. 
Furthermore, binding constants (Kb) were also determined for copper complexes of L ' , L^ 
and L^  as 2.1 X 10^  M ' , 4 X 10^  M"' and 7.8 x 10^  M '^, respectively. The difference in 
binding constants of the three complexes to DNA further support that the functional 
groups on the side chains of macrocycle play a key role in deciding the mode and extent 
of binding of complexes to DNA. 
Competitive ethidium bromide binding study was employed to understand the mode of 
DNA interaction of [Cu(L')]Cl2, [Cu(L^)]Cl2 and [Cu(L^)]Cl2 complexes. The addition of 
the complexes to DNA pretreated with EthBr causes appreciable reduction in emission 
intensity, indicating that the complexes compete with EthBr in binding to DNA (Figure 
13). The quenching constants Ksv were determined by Stem-Volmer equation. The values 
for the copper complexes L , L and L were 1.34, 0.74 and 0.39, respectively. 
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Figure 13. Emmision spectra ofEB bound to DNA in the absence (...) and presence (- ) 
of the (a) fCuL'jCh (b) fCuL^JCh (c) [CuL^JCh 
Cyclic voltammetry is the most effective and versatile electroanalytical technique 
available for the mechanistic study of redox systems [128]. Complexes [Cu(L')]Cl2, 
[Cu(L^)]Cl2 show irreversible redox behaviours with low Ipc/Ipa values while [Cu(L^)]Cl2 
exhibits reversible CV. Redox potential of the complex follow the trend [Cu(L')]Cl2 
>[Cu(L )]Cl2 >[Cu(L )]Cl2 illustrating the ability of the hexaazamacrocycles to stabilize 
the Cu(I) state. The more decrease of the peak current for complex [Cu(L^)]Cl2 than that 
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of [Cu(L^)]Cl2 suggest the stronger binding affinity complex [Cu(L^)]Cl2 to DNA (Figure 
14). 
Figure 14. Cyclic voltammogram offCuLJCh in the absence (-) and in presence (inner 
line) of DNA 
Viscosity measurements were also carried out to understand the binding mode of these 
complexes [Cu(L')]Cl2, [Cu(L^)]Cl2 and [Cu(L^)]Cl2 with CT DNA. In presence of 
[Cu(L^)]Cl2, there was no obvious effect on the relative specific viscosity CT DNA 
whereas complexes [Cu(L')]Cl2 and [Cu(L^)]Cl2 decreased the viscosity of DNA. The 
decrease in viscosity may be explained by a binding mode, which produced bends or 
kinks in DNA (Figure 15). 
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Figure 15. Effect of increasing amounts offCul'jCh (? ) fCuL^JCh (?) [CuL^JCh (*)on 
the relative specific viscosity ofCTDNA 
A series of macrocyclic /intercalator adducts have been prepared from cyclam and the 1-
and 2-substituted anthraquinones (l-[(2-aminoethyl)amino]anthracene-9,10-dione 
(lC2mac), l-[(3-aminopropyl)amino]anthracene-9,10-dione (lC3mac), 2-[(3-
aminopropyl)amino] anthracene-9,10-dione (2C3mac) (Figure 16). These adducts and 
their Cu(II) complexes depict excellent DNA binding properties. UV spectrophotometric 
titrations were carried out to compare the affinities of (lC2mac) and its copper complex 
with salmon sperm DNA [129]. 
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Figure 16. Cyclam/anthraquinone macrocyclic addiict. 
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With increasing concentration of the DNA, a steady decrease in absorbance was observed 
(Figure 17). The apparent binding constants obtained from the half-reciprocal plots were 
found to be 4.7.10^ M'' and 6.2.10^ M ' for (lC2mac) and (Cu-lC2mac), respectively 
suggesting that the metal plays an important role in determining the affinity of the 
complex for DNA. 
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Figure 17. UV spectrophotometric titration curves for (a) lC2mac and (b) Cu-lC2mac. 
The DNA binding of the cyclam/anthraquinone adducts and their metal complexes were 
compared by reacting them with plasmid DNA. The binding assays revealed that addition 
of the macrocycle had a strong influence on the binding of the intercalator moiety. This 
was attributed to the hydrogen bonding association between the macrocycle and the 
DNA. Complexation of the copper to the (lC2mac) adduct substantially modifies the 
binding of the complex as indicated by the lower concentrations required to fully unwind 
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the supercoiled DNA. The dipositive charge of copper within the macrocycle and also the 
availability of the nucleophilic sites in the axial positions of the Cu(II) results in the 
increased DNA binding and/or unwinding (Figure 18). 
(a) (b) 
Figure 18. Gel electrophoresis pattern of pBR322 plasmidDNA treated with (a)lC2mac 
and (b) Cu-lC2mac. 
Macrocyclic SchifF base dinuclear Cu(II) complex of the formula [Cu2LCl2]Cl2.3H20, 
where L = bis-p-xyxlyl BISDIEN was synthesized and characterized by L. N. Ji et al 
[130], The interaction of the complex with calf thymus DNA was investigated by 
electronic absorption spectra, fluorescence spectroscopy, cyclic voltammetry and 
viscosity measurements. The addition of CT DNA to the metal complex results in an 
appreciable decrease in absorption, intensity (hypochromism) indicating interaction 
between the dinuclear complex and CT DNA. Structurally, the ligand provides the 
aromatic moiety extending from the metal centre to overlap with the DNA base pairs by 
an intercalative binding mode (Figure 19,20). 
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Figure 19. Chemical structure of the bis-p-xylylBISDIEN ligand. 
Wavelength (nm) 
Figure 20. Absorption spectra of [Cu2LCl2]Cl2.3H20, in the absence (...) and presence 
(-) of increasing amounts ofDNA. 
Emission titrations of the complex with the EB boimd DNA revealed that the complex 
competes with EB in binding to DNA as depicted in Figure 21 by the reduction in 
emission intensity with increasing concentrations of the complex. The fluorescence 
quenching curve illustrates that the emission quenching of EB bound to DNA by the 
complex was in good agreement with the linear Stem-Volmer equation. 
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Figure 21. (a) Emmision spectra ofEB bound to DNA in the absence (...) and presence 
(- ) of[Cu2LCl2]Cl2.3H20, (b) Stem -Volmer quenching plot. 
Cobalt complexes have received less attention in comparison to other transition metal 
complexes [131-134] although they exhibit interesting metallointercalation and DNA 
cleavage properties [135,136]. Besides this, cobalt containing complexes offer an 
exciting possibility for oral delivery of a wide variety of peptide based drugs- the most 
efficient chemotherapeutics. Co(Ill) is a deactivating carrier system for highly cytotoxic 
organic drugs. These can be released from the metal centre upon reduction to Co(II) and 
exert their activity in hypoxic tissue. Co (III) with its high charge density is a potent 
candidate for hydrolyzing phosphodiester bonds of DNA. E. L. Chang et al [137] have 
developed a kinetically inert Co(III)-cylen based complex (Co(III)-cycmmb) for 
inhibition of the translation of RNA into proteins. 
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The interaction was mediated through the kinetic inertness of Co(III) for the phosphate 
groups of the nucleotides, as well as coordination of Co(III) to the nitrogenous bases. The 
second pathway occurred at longer contact times and was mediated by the hydrolysis of 
the phosphodiester backbone. This was first report that demonstrated use of a metal-
chelate complex to achieve the inhibition of the translation of RNA into proteins (Figiire 
22). 
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Figure 22. Structure of the Co(III)-cycmmb complex 
Dinuclear copper(II) and Zinc (II) complexes containing Bis-TACN macrocycle bridged 
by bis-4-methylphenol were synthesized and evaluated for their DNA binding ability 
[138]. The extent of binding of two complexes to CT DNA was determined by measuring 
their effects on the UV spectroscopy and fluorescence spectra of DNA (Figure 23). Upon 
addition of an increasing amount of DNA to the complexes, hypochromism and slight red 
shift were observed indicating a moderate binding of the complexes with DNA (Figure 
24). The relative binding ability of the complexes was also studied by measuring the 
change in the fluorescence intensity of EB bound DNA upon increasing the complex 
concentration. The emission intensity showed a reduction upon the addition of complexes 
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suggesting an intercalative binding mode. The apparent binding constants for the Cu(II) 
and Zn(II) complexes were found to be 1.0.10^ M ' and 1.1.10^ M"', respectively. The 
similar values result from the intercalation of the 4-methyl phenol group and the 
hydrophobic property of the rigid macrocyclic ligand, which facilitates DNA binding. 
The complexes effectively promote the cleavage of plasmid DNA via the synergistic 
mechanism of the metal ions with the rigid ligand framework. 
Figure 23. Structure of bridged bis-TACN macrocyclic ligand. 
Figure 24. Absorption spectra of dimiclear (a) Cu(II) and (b) Zn (II) complexes of bis-
TACN macrocycle. 
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Nickel plays versatile and sometimes controversial role in living systems [139]. The 
molecular basis of carcinogenic nickel compounds is quite elusive because they are 
weakly mutagenic in most assay systems and only induce rather weak oxidative stress 
[140,141]. In fact, several nickel complexes have been found to inhibit proliferation of 
diverse cancer cells [142,143]. Nickel (II) affects the DNA repair mechanisms by 
inhibiting the base excision repair (BER) and nucleotide excision repair (NER) processes 
[144,145], which may become a potential merit in the design of antitumour agents. It is 
known that cisplatin-DNA adducts are repaired in cells primarily through the NER 
pathway [146]. As a platinum group metal, nickel(II) may share some similarity with 
platinum(II). Therefore, if DNA could be one of the cellular targets for nickel 
compounds, their effects on DNA function could be enhanced by the inhibition of DNA 
repair process. 
Macrocyclic complex [Ni(CR)] (€104)2 where CR = [2,12-dimethyl-3,7,ll,17-
tetraazabicyclo-[11.3.1]heptadeca-l(17),2,ll,13,15-petaenato] was prepared by the 
template condensation reaction using 2,5 diacetyl pyridine and bis-(3-aminopropylamine) 
while complex [Ni(cyclam)](C104)2 (where cyclam= 1,4,8,11 tetraazacyclotetradecane) 
was obtained by the reaction between Ni(C104)2.H20 and cylcam at ratio of 1:1 in 
aqueous EtOH solution (Figure 25). Interaction of these complexes with nucleotides 
GMP, AMP and ApG in aqueous solution has been monitored by 'H, '^N N M R and UV 
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spectroscopy. The complex NiCR oxidized GMP gradually but do not affect AMP 
significantly [147]. 
H,C. ^ *V^CHj ,NHHN 
NH u HN ^NHHN 
Figure 25. Structure of CR (CR=[2.12-dimethyl-3,7,11.17-tetraazabicyclo-
[11.3.1]heptadeca-l(17),2,ll,13,15-petaenato]) and cyclam (cyclam=1,4,8,11 
tetraazacyclotetradecane). 
Chemical nucleases have become an invaluable research tool in the fields of biology, 
bioinorganic chemistry, therapy and molecular biology [148,149]. Chemical nucleases 
are compoimds that mimic the action of enzymatic nucleases and are often dependent on 
their active sites including metal ions particularly Zn(II), Mg(II) and Fe(II), owing to 
their ability to act as Lewis acids [150]. Chemical nucleases are smaller than enzymes 
and capable to attack macromolecular regions that are inaccessible to enzymes and also 
their specificity and efficiency may be modulated [151]. In recent years, many artificial 
metalloenzymes have been suggested as substitutes for natural enzymes to cleave DNA. 
Many complexes of transition metal ions have been designed and studied as artificial 
cleavage agents. Among the commonly used ligands 1,4,7,10-tetraazacyclododecane 
(cyclen) has a special structure and can coordinate with most metal ions (transition metal 
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ions and lanthanide ions) [152-154]. Therefore, metal cyclen complexes were widely 
used in DNA recognition, cleavage and enzyme mimics [155-157]. Many nucleases carry 
one or more metal centres. In most cases synergistic effects exist between the metal 
centres. Polyaza macrocyclic ligand 3,6,9,17,20,23-hexaa2atricyclo[23.3.1.1] triaconta-
l(29),ll(30),12,14,25,27-hexaene (BMXD) was first synthesized in 1990 [158]. The 
ligand consists of a macrocycle formed by two diethylenetriamine moieties separated by 
two m-xylyl bridges, and is capable of coordinating one or two Cu(II) centers via its 
diethylene triamine moieties (Figure 26). The Cu2-BMXD complex was capable of 
undergoing DNA cleavage reaction via an oxidative pathway with reasonably high 
efficiency [159]. 
N Cu ,Cu---N 
Figure 26. Chemical structure of the [CU2BMXD] complex. 
Although there are compounds that are capable of performing remarkable hydrolytic 
cleavage of DNA, oxidative agents that cleave DNA are far more superior. Similarly, a 
series of multinuclear polyamine metal complexes containing chiral dipeptide linkage 
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were synthesized and used as artificial nuclease enzyme models [160]. Burstyn et al have 
studied a series of macrocyclic Cu(II) complexes and they have proposed a mechanism of 
DNA hydrolysis and shown the importance of macrocyclic ring size and substituents on 
the ring for reactivity [161-163]. The reactivity of DNA cleaving agents was strongly 
enhanced when their structures comprised groups having high affinity for the DNA. The 
binding subunits increase the local concentration of the catalyst at the binding site leading 
to the acceleration of the reaction. M. Chikira et al appended an acridine moiety to 1,4,7-
triazacyclononane ([9]aneN3) complex. The conjugation of the metal complex with the 
intercalating group resulted in a higher cleavage activity both in the oxidative and 
hydrolytic cleavage mechanisms [164] (Figure 27). 
NH 
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Figure 27. Macrocyclic artificial DNA cleavage agents. 
Zinc is the most abundant trace intracellular element and plays an important role in both 
genetic stability and function [165]. Mechanistically, zinc has a significant impact on 
DNA as a component of chromatin structure, DNA replication and transcription and 
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DNA repair [166]. Due to its good Lewis acidity, redox inactivity, rapid ligand exchange 
and less toxicity Zn(II) is frequently encountered in both natural and artificial nucleases 
[167]. Xiao-Qi Yu have designed and synthesized the conjugate ligand of cyclen-uracil 
and correlated macrocyclic polyamine Zn(II)complexes having DNA cleaving activity 
(Figure 28). These complexes have special properties; i) uracil as a nucleobase was 
favourable to recognize DNA at low concentrations and ii) the metal ion in the complex 
was bound to imide of uracil group through an intermolecular mode to form unique and 
stable supramolecular complexes, which benefits the DNA cleavage process [168,169]. 
Kimura and co-workers have also demonstrated that Zn(II) complexes of 12-membered 
macrocyclic tetraamine selectively interacts with uridine and thymidine nucleotides 
through specific Zn^ ^ imide N-bonding [170]. 
•R—N ; = 0 
Figure 28. Uracil conjugated Zn(II) macrocyclic complex. 
A series of bimetallic systems have been synthesized and investigated for their catalytic 
cleavage activity of DNA models and DNA itself, as the catalytic efficiency of many 
natural metallonucleases often relies on the cooperative action of two or more metal ions. 
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The two metal ions not only increase the effect of Lewis acid catalysis but also make 
possible other activation modes, such as leaving group activation [171]. R. Breslow 
prepared a bimetallic macrocyclic complex by connecting two tridentate macrocyclic 
ligand with a rigid 4,4'-biphenyl linker (Figure 29). The reactivity towards several 
phosphate esters increased 5 times than the corresponding monometallic system [172]. 
'.^.. rf 
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2+ Figure 29. Structure of the ditopic bimetallic Zn complex. 
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Present work 
The interaction of metal complexes with nucleic acids and their constituents is of central 
importance to many aspects of their structure and fimction. These complexes offer 
opportunity to explore the effects of central metal atom, the ligand and the coordination 
geometries on the binding events. Tailored multifunctional ligands for metal-based 
medicinal drugs play an integral role in modulating the potential toxicity of a 
metallodrug. In metal- based drug candidates, the metal ion organizes the organic ligands 
in the three dimensional space permitting the site-specific interaction by matching the 
shape, symmetry and functionality of metal complexes to that of DNA target. Such an 
approach complements the molecular diversity in the quest for the discovery of 
therajjeutic compounds with superior biological activity. 
Macrocycles are important and ubiquitous ligands in transition metal coordination 
chemistry, imparting thermodynamic and kinetic stabilities to their complexes uncommon 
or non-existent with other acyclic ligands. The molecular topology of the ligand 
framework assists these metal ions to achieve specificity for the target site DNA and 
enhances their DNA binding affinity. On account of the unique coordination and 
structural properties of pendant armed macrocyclic complexes and their roles in 
bioinorganic chemistry, new macrocyclic complexes of 4,15-bis(2-hydroxyethyl)-
2,4,6,13,15,17-hexaazatricyclodocosane were synthesized from diaminocyclohexane, 
formaldehyde and 2-aminoethanol. Complexes bearing cyclohexylamine moiety, a non-
planar amine ligand are known to affect the kinetics and cytotoxicity. The molecular 
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planar amine ligand are known to affect the kinetics and cytotoxicity. The molecular 
architecture of these complexes bearing -NH and -OH groups of appended arms with 
two cyclohexane rings, provides a rationale to explore their DNA binding properties. 
The binding of these complexes with CT DNA was studied by UV/Vis, fluorescence 
spectroscopy, viscosity and cyclic voltammetry. These complexes exhibit efficient DNA 
binding activity, which was ascertained by their interaction with CT DNA; furthermore 
specific binding behaviour was studied with 5'GMP employing UV/Vis and NMR 
spectroscopy. 
Benzimidazoles are very useful subunits for the development of molecules of 
pharmaceutical or biological interest. A new series of benzimidazole-derived dinuclear 
O2S2 donor macrocyclic complexes were synthesized. Their DNA binding abilities were 
investigated by UV/Vis and fluorescence spectroscopy, cyclic voltammetry and viscosity 
measurements. The results suggest that the complexes bind to DNA by a partial 
intercalative binding mode. The cleavage of supercoiled pBR322 plasmid DNA by the 
Cu(II) complex in absence or presence of reducing agent was observed using gel 
electrophoresis. The complex exhibited an efficient nuclease like activity via an oxidative 
cleavage mechanism. 
Complexes featuring two or more metal centres held at an optimum distance can 
modulate the sequence selective recognition of the biological target. Therefore, an 
attempt was made to synthesize bis-macrocyclic complexes via in situ one pot template 
condensation reaction of pyridynyl, an aromatic nitrogen-nitrogen linker, formaldehyde 
37 
of these complexes with DNA. Interaction with 5'GMP was studied by absorption 
spectroscopy. 
Coumarin derivatives have been proven to fimction as chemotherapeutic agents with a 
variety of biological activities including the anticancer activity. A new series of metal 
complexes were synthesized from a coumarin ligand 3-acetoacetyl-7-methyl-pyrano-(4,3-
b)-pyran-2,5-dione and diaminocyclohexane via a template reaction to give a schiff base 
type macromolecule. The DNA binding affinity of the ligand and the copper complex 
was evaluated by electronic absorption spectroscopy and flourescence spectroscopy. 
Interaction with 5'GMP was elucidated by absorption and NMR spectroscopy. In vitro 
antitumour activity of the ligand against different human cancer cell lines were 
determined using standard protocols for cell viability. The ligand exhibited highest 
growth inhibiting effect against CNS cancer SNB-75 cell lines. It is inferred that the 
metal complexes will possess greater cytotoxic effect then the free ligand since chelation 
enhances the inhibitory power of the ligands. 
CHAPTER II 
Experimental 
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CHAPTER II 
EXPERIMENTAL METHODS 
The following techniques were employed. 
1. Characterization techniques 
1.1 Infrared spectroscopy 
1.2 Ultra-violet and visible spectroscopy 
1.3 Nuclear magnetic resonance spectroscopy 
1.4 Electron paramagnetic resonance spectroscopy 
1.5 Mass spectroscopy 
1.6 Molar conductance measurements 
2. DNA binding studies 
2.1 Cyclic voltammetry 
2.2 Absorption spectral studies 
2.3 Fluorescence spectral studies 
2.4 Gel electrophoresis 
2.5 Viscometry studies 
1. Characterization techniques 
1.1 Infrared spectroscopy 
The infrared spectroscopy is a useful technique to characterize a compound. It results 
from transition between vibrational and rotational energy levels. IR region of the 
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electromagnetic spectrum covers a wide range of wavelength from 200 to 4000 cm' . It 
has been found that in IR absorption, some of the vibrational frequencies are associated 
with specific groups of atoms and remain same irrespective of the molecules in which the 
group is present. These are called characteristic frequencies [173] and their constancy 
results from the constancy of bond force constants from molecule to molecule. The 
important observation that the IR spectrum of a complex molecule consists of 
characteristic group frequencies makes IR spectroscopy, unique and powerful tool in 
structural analysis. 
1.2 Ultraviolet and visible spectroscopy 
When a molecule absorbs radiation, its energy is increased. This increased energy is 
equal to the energy of the incident photon expressed by the relation 
E = hv 
E =hc/X 
where h is Planck's constant, v is the frequency, X is the wavelength of the radiation and 
c is the velocity of light. Most of the compoimds absorb light in the spectral region 
between 200 and 800 nm resulting in the excitation of electrons of the molecules from 
ground state to higher electronic states. In transition metals, all the five'd' orbitals viz. 
9 7 7 
dxy, dyz, dxz, dz and dx -y are degenerate. However, in coordination compounds due to the 
presence of ligands, this degeneracy is destroyed and d orbitals split into two groups t. 
g 
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(dxy, dyz and dxz) and Cg (d^ ^ and dx .^y )^ in an octahedral complex and t and e in a 
tetrahedral complex. The set of tjg orbitals goes below the original level of degenerate 
orbitals in octahedral complexes and the case is reversed in tetrahedral complexes (Figxire 
30a-b). 
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Figure 30a. Splitting of the d energy levels in an octahedral complex. 
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Figure 30b. Ligand field splitting of a tetrahedral complex, 'g' subscript is omitted in Tj 
symmetry. 
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At energy higher than the ligand field absorption bands, we commonly observe one or 
more very intense bands that go off scale unless log e is plotted. These are the charge 
transfer bands, corresponding to electron transfer processes that might be either ligand —• 
metal (L —>• M) or metal -* ligand (M -* L). In case of octahedral complexes M —» L 
transitions occur for metal ion complexes that have filled, or nearly filled, t2g orbitals with 
ligands that have low lying empty orbitals. The L -> M charge-transfer (C-T) spectra 
have been studied more thoroughly. The electron density is transferred from the ligand to 
the metal. This is favoured when the central metal has a high oxidation state, and is 'short 
of electrons'. The ligand n orbitals are lower in energy than the metal t2g orbitals. No net 
oxidation-reduction usually occurs, because of the short lifetime of the excited state 
[174]. 
1.3 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The 
NMR spectroscopy is concerned with nuclei having nuclear spin quantum number 
1 = 1/2, example of which include 'H , '^C, ^ 'P , '"Sn and '^F. 
For a nucleus with 1 = 1/2, there are two values for the nuclear spin angular momentum 
quantum number mi = ±1/2 which are degenerate in the absence of a magnetic field. 
However, in the presence of the magnetic field, this degeneracy is destroyed such that the 
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positive value of mi corresponds to the lower energy state and negative value to higher 
energy state separated by AE. 
In an NMR experiment, one applies strong homogeneous magnetic field causing the 
nuclei to presses. Radiation of energy comparable to AE is then imposed with radio 
frequency transmitter equal to precision or Larmor fi-equency and the two are said to be 
in resonance. The energy can be transferred from the source to the sample. The NMR 
signal is obtained when a nucleus is excited from low energy to high energy state. 
1.4 Electron paramagnetic resonance spectroscopy 
EPR spectroscopy [175] is the branch of absorption spectroscopy in which radiation 
having frequency in the microwave region is absorbed by molecules possessing electrons 
with unpaired spins. The unpaired electrons in radicals or in complexes of transition 
metal centers with only partially filled d orbitals features a spin, the orientation of which 
in a magnetic field can give rise to two energetically different states. For an electron of 
spin S = 1/2, the spin angular momentum quantum number will have values of ms = ±1/2. 
In absence of magnefic field, the two values of ms i.e. +1/2 and -1/2 will give rise to a 
doubly degenerate spin energy state. If a magnetic field is applied, this degeneracy is 
lifted and leads to the non-degenerate energy levels. The low energy level will have the 
spin magnetic moment aligned with the field and correspond to the quantum number ms = 
-1/2. On the other hand, the high energy state will have the spin magnetic moment 
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opposed to the field and correspond to the quantum number m^ = +1/2. The energy E of 
the transition is given by; 
E = hv = gPHo 
Where h is Plank's constant, v the frequency of radiation, p the Bohr magneton, Ho the 
field strength and g the spectroscopic splitting factor. 
The magnitude of g is characteristic for the paramagnetic system and depends upon the 
orientation of the molecule with respect to the magnetic field. From the observed value of 
g it is possible to determine oxidation and spin states or even details in the coordination 
sphere of the metal centers. If the paramagnetic radical or ion has g value independent of 
the orientation of the crystal it is said to be isotropic and if the value of g depends on the 
orientation of the crystal and is said to be anisotropic. 
1.5 Mass spectroscopy 
At electron beam energy of about 9 to 15 electron volts, depending on the molecule 
involved, a molecular ion is formed by interaction with the beam electrons. Recognition 
of the parent ion (actually a radical ion) is of great importance because it gives the 
molecular weight of the sample [176]. At this point, the molecular weight is an exact 
numerical molecular weight not the approximation obtained by the all other molecular 
weight procedures. Mass spectra is usually obtained at an electron beam energy of 70 
electron volts and under these conditions numerous fragment ions (including the parent 
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ions) versus their relative concentrations constitutes the mass spectrum of the samples. 
The fragmentations occur on the basis of mass/charge (m/z). The largest peak in the 
spectrum is called base peak and assigned a value of 100 %. The other peaks are reported 
as percentage of the base peak. 
1.6 Conductance measurements 
The conductivity measurement is one of the simplest and easily available techniques used 
to study the nature of the complexes. It gives direct information regarding whether a 
given compound is ionic or covalent. For this purpose, the measurement of molar 
conductance (Am) which is related to the conductance value in the following manner is 
made. 
cell constant x conductance 
Am = 
concentration of solute expressed in mol cm" 
Conventionally, solutions of 1x10"^  M strength are used for the conductance 
measurements. Molar conductance values of different types of electrolytes in a few 
solvents are given as, 1:1 electrolyte has a value of 80-115 ohm"' cm^ mol"' in MeOH, 
65-90 ohm"' cm^ mol"' in DMF, 78-80, 50-70 ohm"' cm^ mol"' DMSO and 35-45 ohm"' 
cm^ mol' in EtOH [177,178]. Similarly a solution of 2:1 electrolyte has a value of 160-
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220 ohm"' cm^ mol' in MeOH, 130-170 ohm"' cm^ mol"' in DMF and 70-90 ohm"' cm^ 
mol"' in EtOH. 
2. DNA binding studies 
Calf thymus DNA was procured from Sigma Chemical Company and Tris-base was 
obtained from E. Merck. All the experiments involving interaction of the complexes with 
CT DNA were conducted in buffer containing Tris (0.01 M) adjusted to pH 7.2 with 
hydrochloric acid. The CT DNA was dissolved in Tris HCl buffer and was dialyzed 
against the same buffer overnight. Solutions of CT DNA gave ratios of UV absorbance at 
260 and 280 nm above 1.8, indicating that the DNA was sufficiendy free of protein [179]. 
DNA concentration per nucleotide was determined by absorption specfroscopy using the 
molar absorption coefficient 6600 dm^ mol"' cm"' at 260 nm [180]. The stock solution 
was stored at 4°C. 
2.1 Cyclic voltammetry 
Cyclic voltammetry involves the measurement of current-voltage curves under diffusion 
controlled, rnass transfer conditions at a stationary elecfrode, utilizing synmietrical 
triangular scan rates ranging from a few millivolts per second to hundred volts per 
second. The triangle returns at the same speed and permits the display of a complete 
polarogram with cathodic (reduction) and anodic (oxidation) waveforms one above the 
other. Two seconds or less is required to record a complete polarogram [181]. 
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Consider the reaction 
O + ne • R (i) 
Assuming semi-infinite linear diffusion and a solution containing initially only species O. 
With the electron held at a potential Ei where no electrode reaction occurs. The potential 
is swept linearly at v v/sec so that the potential at any time is 
E(t) = Ei-vt 
or Epeak = E°-0.0285 
The rate of electron transfer is so rapid at the electrode surface that species O and R 
immediately adjust to the ratio according to the Nemst equation, which is as follows., 
Co (0,t) = Co* - [nFA(7rDo)'^ ]-' J I(7c)(t-T)-"^ dx (ii) 
I = nFACo*(7iDoCT)'^ x(CTt) (iii) 
Redox (electron-transfer) reactions of metal complexes can be investigated by cyclic 
voltammetry. An electrode is immersed in a solution of the complex and voltage is swept 
while current flow is monitored. No current flows until oxidation or reduction occurs. 
After the voltage is swept over a set range in one direction, the direction is reversed and 
swept back to the original potential. The cycle may be repeated as often as desired. 
Figure 31 shows the cyclic voltammograms (CV) for a reversible one-electron redox 
reaction such as, 
CpFe(CO)LMe • CpFe(CO)LMe^ + e" 
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Sweeping the potential in an increasing direction oxidize the complex as the anodic 
current la flows; reversible reduction of CpFe(CO)LMe* generates cathodic current Ic on 
the reverse sweep. The magnitude of the current is proportional to the concentration of 
the species being oxidized or reduced. 
The measured parameters of interest on these cyclic voltammograms are Ipa/Ipc the ratio 
of peak currents, Epa - Epc the separation of peak potentials and the formal electrode 
potential E°. For a Nemstian wave with stable product, the ratio Ipa/Ipc - 1 regardless of 
scan rate, E° and diffusion coefficient, when Ipa is measured from the decaying cixrrent as 
a base line. The difference between Epa and Epc (AEp) is a useful diagnostic test of a 
Nemstian reaction. Although AEp is slightly a function of E°, it is always close to 
2.3RT/ nF. 
0 Switching time, X 
(a) (b) 
Figure 31. (a) Cyclic potential sweep (b) Resulting cyclic voltammogram 
The technique yields information about reaction reversibilities and also offers a rapid 
means of analysis for suitable systems. The method is particularly valuable to study 
interaction of metal ions to DNA as it provides a usefiil compliment to other methods of 
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investigation, such as UVA^is spectroscopy. Cyclic voltammetric studies were 
accomplished on a CH Instrument Electrochemical analyzer using a three-electrode 
configuration comprised of a Pt wire as the auxiliary electrode, a platinum micro-cylinder 
as the working electrode and Ag/AgCl as the reference electrode. Electrochemical 
measurements were made imder nitrogen atmosphere. All electrochemical data were 
collected at 298 K and are uncorrected for junction potentials. 
2.2 Absorption spectral studies 
In a closed constant volume system, the rate of a chemical reaction is defined as the rate 
of change of the concentration of any of the reactants and products with time. The 
concentration can be expressed in any units of quantity per imit volume e.g. moles per 
liter, moles per cubic centimeter. The rate will be defined as positive quantity regardless 
of the component whose concentration change is measured. 
The rate of a chemical reaction is not measured directly instead the concentration of one 
of the reactants or products is determined as a fiincfion of time. A common procedure for 
determining the reaction order is to compare the experimental results with integrated rate 
equations for reactions of different orders. For a first order rate equation, integrating by 
separate variables using integration limits such that at t = 0, c =^  Co and at t = t, c = c. 
[182]. 
-dc/dt = kc 
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or In (CQ/C) = kt 
The intrinsic binding constant Kb of the complex to CT DNA was determined from 
equation (1), through a plot of [DNA]/ e^-Cf vs [DNA], where [DNA] represents the 
concentration of DNA, and Ea, Cf, and Sb the apparent extinction coefficient (Aobs /[M]), 
the extinction coefficient for free metal complex (M), and the extinction coefficient for 
the free metal complex (M) in the fully bound form, respectively. In plots of [DNA]/ea-Ef 
vs. [DNA], Kb is given by the ratio of slope to intercq)t [183,184]. These absorption 
spectral studies were performed on USB 2000 Ocean Optics and Shimadzu UV-1700 
PharmaSpec UVA^is spectrophotometers. 
[DNA] / |8a-efl = [DNA]/|8a-£d +l/Kb|ea-8f| (1) 
Absorption spectral titration experiments were performed by maintaining a constant 
concentration of the complex and varying the nucleic acid/nucleotide concenfration. This 
was achieved by diluting an appropriate amount of the metal complex solutions and CT 
DNA/5'GMP stock solutions while maintaining the total volume constant. This results in 
a series of solutions with varying concentrations of CT DNA/5'GMP but a constant 
concentration of the complex. The absorbance (A) was recorded after successive 
additions of CT DNA/5'GMP. While measuring the absorption spectra an equal amount 
of CT DNA/5'GMP was added to both the compound solution and the reference solution 
to eliminate the absorbance of the CT DNA/5'GMP itself 
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2.3 Fluorescence spectral studies 
When molecules that have absorbed light are in a higher electronic state, they must lose 
their excess energy to return back to the ground state. If the excited molecule returns to 
the ground state by emitting light, it exhibits fluorescence and spectrum thus obtained is 
called emission spectrum. This phenomenon is generally seen at moderate temperature in 
liquid solution. The emission spectrum is obtained by setting the excitation 
monochromator at the maximum excitation wavelength and scanning with emission 
monochromator. Often an excitation spectrum is first made in order to confirm the 
identity of the substance and to select the optimum excitation wavelength. Further 
experiments were carried out to gain support for the mode of binding of complexes with 
CT DNA. Non-fluorescent or weakly fluorescent compounds can often be reacted with 
strong fluorophores enabling them to be determined quantitatively. On this basis 
molecular fluorophore EthBr was used which emits fluorescence in presence of CT DNA 
due to its strong intercalation. Quenching of the fluorescence of EthBr bound to DNA 
were measured with increasing amount of metal complexes as a second molecule and 
Stem-Volmer quenching constant K was obtained from the following equation 2 [185]. 
I o / I = l + K r (2) 
where r is the ratio of total concentration of complex to that of DNA and IQ and I are the 
fluorescence intensities of EthBr in the absence and presence of complex. Binding 
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constant K of the metal complexes was also determined from equations 3 and 4 
(Scatchard equations) by emission titration [186,187]. 
CF = C T ( I / I O - P ) ( 1 - P ) (3) 
r/CF = K(n-r) (4) 
Where Cp is the free probe concentration, Cj is the total concenfration of the probe added 
I and lo are fluorescence intensities in presence and absence of CT DNA, respectively and 
P is the ratio of the observed fluorescence quantimi yield of the bound probe to that of the 
free probe. The value P was obtained as the intercept by extrapolating from a plot of I/Io 
vs 1/ [DNA], r denotes ratio of CB (=CT-CF) to the DNA concentration i.e., the bound 
probe concentration to the DNA concentration, K is the binding constant and CF, is the 
free metal complex concentration and "n" is the binding site nimiber. Emission intensity 
measurements were carried out using Hitachi F-2500 spectrofluorometer at room 
temperature. 
2.4 Gel electrophoresis 
Gel electrophoresis is a technique widely used for separation and analysis of charged 
biomolecules like nucleic acids [188,189]. Any charged biomolecule migrates when 
placed in an electric field. The ratio of migration of a molecule depends on its net charge, 
size, shape and the applied current. This can be represented as follows 
V = E.q / f 
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Where V = velocity of migration of the molecule, E = electric field in volts/cm, q = net 
charge on the molecule, f = frictional coefficient which is function of mass and shape of 
molecule. The movement of a charged molecule in an electric field is often expressed in 
terms of electrophoretic mobility (|i), which is defined as the velocity per unit of electric 
field. 
H = V / E = E .q / f .E 
ji = q / f 
For molecules with similar conformation, "f " varies with size but not with shape. Thus 
electrophoretic mobility (ji) of a molecule is directly proportional to the charge density 
(charge/mass ratio). Molecules with different charge/mass ratio migrate under the electric 
field at different rates and hence get separated. This is the basic principal for all the 
electrophoretic techniques. Depending upon the nature of support medium, 
electrophoresis is of different types such as paper, starch, polyacrylamide and agarose gel 
electrophoresis. We have opted agarose gel electrophoresis, because agarose gels are 
more porous as compared to polyacrylamide gels and are, therefore, used to fi^ctionate 
large macromolecules such as DNA that caimot be readily penetrate into and move 
through other types of supporting materials. Agarose is a linear polymer of D-galactose 
and 3,6-anhydro-L-galactose. When an electric field is applied across agarose gel, DNA 
molecules that are negatively charged at neutral pH, migrates towards oppositely charged 
electrode at rates determined by their molecular size and conformation. DNA molecules 
of the same size but with different conformation travel at different rates. The order of 
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migration velocity in the increasing order of various forms of DNA is: supercoiled DNA 
> linear double strand DNA > open circular DNA. 
2.5 Viscometry studies 
The hydrodynamic changes are the consequence of the change in length of the molecule, 
the diminished bending between layers and the diminished length-specific mass. 
Viscosity measurements were carried out using Ostwald's viscometer at 29 ± 0.01 °C. 
Flow time was measured with a digital stopwatch. Each sample was measured three times 
and an average flow time was calculated. Data were presented as (r|/r|o) versus binding 
ratio ([M]/[DNA]), [190,191] where r| is a viscosity of DNA in the presence of complex 
and r|o is the viscosity of DNA alone. Viscosity values were calculated from the 
observed flow time of DNA containing solution (t >100s) corrected for the flow time of 
buffer alone (to), ti = t- to. 
CHAPTER m 
Synthesis, Spectroscopic Studies of New Water-Soluble Co(II) and 
Cu(II) Macrocyclic Complexes of 4,15-bis(2-hydroxyethyl)-
2,4,6,13,15,17- hexaazatricyclodocosane: Their Interaction Studies with 
Calf Thymus DNA and Guanosine 5' Monophosphate 
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CHAPTER III 
Experimental 
Cobalt chloride hexahydrate (C0CI2. 6H2O), nickel chloride hexahydrate (NiCli. 6H2O), 
copper chloride dihydrate (CUCI2.2H2O), Tris-base, formaldehyde, ethanolamine (E. 
Merck) and 1, 2-dianiinocyclohexane (Fluka) were used as received. Calf thymus DNA 
(CT DNA) and guanosine 5'monophosphate disodiimi salt (5'GMP) were purchased from 
Sigma chemical Co. and Fluka, respectively. All reagent grade compounds were used 
without further purification. Carbon, hydrogen and nitrogen contents were determined 
using Carlo Erba analyzer Model 1108. Molar conductances were measured at room 
temperature on a Digisun Electronic conductivity Bridge. Fourier-transform ER (FTIR) 
spectra were recorded on an Interspec 2020 FTIR spectrometer. UVA^is spectra were 
recorded on a UV-1700 Pharma Spec Shimadzu spectrophotometer in H2O and the data 
were reported as A-max/nm. The EPR spectrum of the copper complex was acquired on a 
Varian E 112 spectrometer using X-band frequency (9.1GHz) at liquid nitrogen 
temperature in solid state. The ' H and *^ C NMR spectra were obtained on a Bruker DRX-
300 spectrometer operating at room temperature. Chemical shifts were reported in ppm. 
Electrospray mass spectra were recorded on Micromass Quattro II triple quadrupol mass 
spectrometer. Molecular modeling of the complex was carried out by using CS Chem 
Draw 3D Pro 5.0. 
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All the experiments involving interaction of the complex with CT DNA were performed 
in twice distilled buffer containing tris (hydroxymethyl)-aminomethane (Tris, 0.01 M) 
and adjusted to pH 7.5 with hydrochloric acid. Solution of 5'GMP was prepared in 
double distilled water. NMR experiments with 5'GMP were carried out in D2O on a 
Bruker Avance II 400 NMR spectrometer at 25 ^C. Cyclic voltammetric studies were 
performed on a CH Instrument Electrochemical analyzer in a single compartmental cell 
with 5 mM Tris-HCl/50 mM KCl buffer as supporting electrolyte. A three-electrode 
configuration was used comprising of a Ft wire as auxiliary electrode, platinum micro 
cylinder as working electrode and Ag/AgCl as the reference electrode. Electrochemical 
measurements were made under a dinitrogen atmosphere. 
Synthesis of 4,15-bis(2-hydroxyethyl)-2,4,6,13,15,17- hexaazatricyclodocosane 
cobalt(II) Dichloride IC20H42N6O2C0 ]Cl2 
To a stirred methanol solution (50 mL) of C0CI2. 6H2O (5.94 g, 25 mmol) were slowly 
added 1,2-diaminocyclohexane (6.08 mL, 50 mmol) formaldehyde (2.8 mL, 100 mmol) 
and ethanolamine (3.07 mL, 50 mmol). The resulting mixture was refluxed for ca 24 h 
until a dark orange colored solution appeared. The volume of the solution was reduced to 
15 mL on a rotary evaporator and then kept in refrigerator overnight. The dark orange 
crystals were separated and washed thoroughly with hexane and then dried in vacuo. 
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Synthesis of 4,15-bis(2-hydroxyethyl)-2,4,6,13,15,17- hexaazatricyclodocosane 
nickel(II) Bichloride [C2oH42N602Ni]Cl2 
The [C2oH42N602Ni]Cl2 complex was prepared by using NiCl2.6H20 (5.92 g, 25 mmol) 
according to the method outlined for complex [C20H42N6O2C0 ]Cl2. The brown coloured 
product obtained was washed with methanol and dried in vacuo. 
Synthesis of 4,15-bis(2-hydroxyethyl)-2,4,6,13,1547- hexaazatricyclodocosane 
copper(II) Dichloride IC2oH42N602Cu]Cl2 
The complex [C2oH42N602Cu]Cl2 was prepared by adopting the procedure given for 
[C2oH42N602Co]Cl2 using CUCI2.2H2O (4.26 gm, 25 mmol). The dark blue coloured 
complex obtained was filtered, washed with hexane and dried in vacuo. 
Results and discussion 
The one step template reaction of 1,2-diaminocyclohexane, formaldehyde and 
ethanolamine in presence of metal chloride salts yielded the Cobalt(II), Nickel(II) and 
Copper(II) macrocyclic complexes of 4,15-bis(2-hydroxyethyl)-2,4,6,13,15,17-
hexaazatricyclodocosane in which 2-hydroxyethyl groups are appended as shown in 
Scheme 1. These complexes are extremely stable in solid state; readily dissolve in H2O, 
MeOH, EtOH, DMF and DMSO. Molar conductivity data for 10'^  M solutions in H2O 
observed in the range -150-200 O'cm^mol"' are in accordance with those expected for 
1 -.2 electrolytes, implying the non-participation of chloride anions in coordination to the 
MCl2 + + HCHO + HO V 
^ 
NH, 
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2+ 
,2CI 
M = Co(II), Ni(II), Cu(II) 
Scheme 1. Proposed structure of complexes [C2oH42N602Co]Cl2, [C2oH42N602Ni]Cl2 and 
[C20H42N6O2CUJCI2. 
metal ion. The important properties and physical data of the complexes are given in Table 
1. The stretching mode v(O-H) in the IR spectra of all the complexes confirm to the 
existence of free hydroxyl groups. Thus, the potentially hexadentate ligand behaves as a 
tetradentate ligand with the central metal ion assuming a square planar coordination 
geometry as also authenticated by the UV/Vis absorption spectroscopy. The molecular 
model of the complex [C2oH42N602Co]Cl2 as depicted in Figure 32 indicates that there is 
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no strain on any bond and angle. The interaction studies of complex [C2oH42N602Co]Cl2 
and [C2oH42N602Cu]Cl2 with CT DNA and guanosine 5'monophosphate in aqueous 
solution were examined by various techniques while [C2oH42N602Ni]Cl2 was synthesized 
only for NMR studies. Molecular architecture of the macrocyclic complexes which, 
contain —NH— and —OH groups of appended arms with two cyclohexane rings, provides 
a rationale to explore their DNA binding propensity. An additional feature is their 
solubility in water — a highly significant physical property of pharmacological 
relevance, as all biochemical reactions are based on small molecules that dissolve in an 
aqueous phase [192]. 
Figure 32. Three dimensional molecular model of the [C2ot'U2N602Co]Cl2 
complex.Colour Scheme Co" Purple; N blue; O red; C gray; H light blue; lone pairs 
pink. 
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I R spectra 
The IR spectra of the complexes [C2oH42N602Co]Cl2, [C2oH42N602Ni]Cl2 and 
[C2oH42N602Co]Cl2 exhibit an intense band in 3100-3130 cm' region due to v(N-H) 
[193] of the coordinated secondary amino group, which was further confirmed by the 
appearance of bands in the 534-550 cm"' range corresponding to v(M-N) vibrations [194]. 
Absorption bands due to v(CH2) vibrations of the cyclohexyl ring and the ethanolamine 
moiety were observed at 2860 - 2931 cm'' and 2367- 2380 cm"' region, respectively 
while a moderate peak at ~ 1600 cm"' was assigned to 5(N-H) vibrations [195]. The 
strong characteristic bands at 1441 - 1452 cm"' and 1043 - 1049 cm"' were associated 
with the C-N and C-0 vibrations of the ethanolamine fragment. The stretching mode of 
the 0-H group observed at ca. 3200 cm' suggests that the oxygen atom does not interact 
with the metal ion [196] (Table 2). Together with these observations, the absence of the 
free -NH2 group stretching modes at ~ 3300 - 3400 cm"' confirmed the condensation and 
the subsequent cyclization resulting in the formation of new macrocyclic complexes. 
NMR Spectra 
The 'H and '^C NMR spectra of the diamagnetic [C2oH42N602Ni]Cl2 complex were 
obtained in D2O solution. The 'H NMR spectrum revealed an intense signal at 4.79 ppm 
assigned to the presence of free -OH protons of the ethanolamine pendant arm as 
observed for the analogous ethanolamine metal complexes [197]. Signature due to the 
two -CH2 groups of the ethylene chain appeared at ~ 3.67 ppm (-CH2OH) and at 3.36 
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ppm (-CH2N), respectively [198,199]. The cyclohexane ring protons were observed in 
the 2.56- 2.86 ppm and 1.44-1.74 ppm range as doublets [200,201] (Table 3). 
The '^C NMR spectrum confirms the ' H N M R data. The '^C NMR spectrum features 
various resonances due to the cyclohexyl ring carbons at 19.00, 20.29, 23.94, 26.70, 
39.13 ppm [202, 203] (Table 4). A doublet appearing at 58.58- 58.85 ppm has been 
assigned to the -CH2OH carbons of ethanolamine moiety [204]. Additional signals at 
54.64 ppm and at 68.62 ppm were observed due to -N-CH2-GHr-0H carbons and - N -
C-N-C-N- carbons of the macrocyclic framework, respectively [205]. 
Electronic absorption spectra 
The electronic spectra of the complexes [C2oH42N6C)2Co]Cl2, [C2oH42N602Ni]Cl2 and 
[C2oH42N602Cu]Cl2 wcrc characterized by strong ligand absorptions at around 224-240 
nm. The visible region of the [C2oH42N602Cu]Cl2 complex exhibited a very broad and 
intense band centered at 570 nm, which was assigned to Big • Aig transition [206, 
207], a characteristic of CUN4 chromophore with the copper ion in the square planar 
environment. The electronic spectrum of the [C2oH42N602Co]Cl2 complex displays two 
main absorption bands; an intense band at 340 nm attributed to the charge transfer (CT) 
transitions; and a broad band at 490 nm ascribed to the d-d transition indicative of the 
square planar Co(II) ion [208]. Similarly, the [C2oH42N6C)2Ni]Cl2 complex exhibits an 
intense charge transfer band at 340 nm. The d-d band due to the Ni(Il) ion of the complex 
[C2oH42N602Ni]Cl2 was not fully resolved, and seemed to be obscured under the charge 
transfer band, which was tailed to near IR region. However, a discernible shoulder 
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appeared at 510 nm, which may be assigned to 'Aig(F) • 'Big(G) transition, typical 
of a low spin d* electronic configuration of square planar Ni(II) ion [209,210]. 
EPR Spectrum 
The solid state X-band EPR spectrum of the [C2oH42N602Cu]Cl2 complex was recorded 
at 77K (liq-N2 temperature) using TCNE as a field marker (2.00277). The spectrum 
exhibits a broad gj. component with the splitting of the g y component, reflecting the 
coupling with the Cu(II) nucleus (I = 3/2). The g n value at 2.19 and gi at 2.05 are quite 
similar to the values reported for other related square planar copper (II) complexes and 
are typical for axially symmetrical Cu(II) complexes with the unpaired electron in the 
dxl ^ orbital with ^Big ground state [211]. The order g n >gj. > gc (2.0023) further confirm 
that the ground state of the Cu(II) is predominantly dx^ - ^. 
Solution stability studies 
To confirm the stability of complexes [C2oH42N602Co]Cl2 and [C2oH42N6C)2Cu]Cl2 in 
buffered solution at various pH values, UVA/^ is and cyclic voltammetric studies were 
performed under conditions similar to those used for DNA binding studies. UVA^is 
spectra of complex [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 exhibited no change in 
the position of the intraligand band over a pH range 2-12 with only minor change in 
intensity. The complexes also display similar spectra over a period of 24 h and no 
precipitation was observed (Figure 33a- b). The non-precipitation after a 24 h time period 
and over a broad pH range suggests the robust nature of these complexes in solution. The 
solution stability of complex [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 were ftirther 
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studied by means of cyclic voltanunetery in the pH range 2-10. The voltammetric 
behaviour of the complexes was found to be reproducible and they exhibited 
quasireversibility [212] typical for one electron transfer process corresponding to 
M(II)/M(I) redox couple (Figure 34a -b) 
30O4I0 
Wavelength KM 
Fig. 33a. UV/Vis absorption spectra of the [C20H42N6O2CUJ Ch complex as a function of 
pH. Conditions: Tris-HCl buffer, 25 C; The curves from top to bottom correspond to pH 
12, 10, 8, 6, 4, 2 respectively. 
Wavelength (nm) 
Figure 33b. UV/Vis absorption spectra of the [C2oH42N602Cu]Cl2 complex after 24 h as 
a function of pH. Conditions: Tris HCl buffer, 25 "C; The curves from top to bottom 
correspond to pH 12, 10, 8, 6, 4, 2 respectively. 
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Figure 34a. Cyc//c voltammetric data for [C2oH42N(,02Co]Cl2 complex at pH i) 2, ii) 4. 
Hi) 6, iv) 8, v) 10. Conditions: 5 mM Tris-HCl/50 mM KCl buffer. 25 "C; scan rate 0 1 
VS'. 
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Figure 34b. Cyclic voltammetric data for [C2oH42N602Cu]Cl2 complex at pH i) 2, ii) 4, 
iii) 6, iv) 8, v) 10. Conditions: 5 mM Tris-HCl/50 mM KCl buffer. 25 "C; scan rate 0.1 
vs-'. 
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Mass spectra 
Electrospray mass spectra in the positive ion mode were recorded for the complexes 
[C2oH42N602Co]Cl2, [C2oH42N602Ni]Cl2 and [C2oH42N602Cu]Cl2. The ESI MS spectrum 
of the [C2oH42N602Cu]Cl2 complex shows the molecular cation peak, [M-Cl]"^ at m/z = 
496 corresponding to a mass loss of 35.45 due to the one chloride ion from the parent 
macrocycle. The spectrum shows some prominent peaks corresponding to the various 
fragments of the complex. The molecular cation during the fragmentation process yields 
the species such as; (C16H35N5OCICU + 2H^ 411; (C,6H32N4ClCu) 378; (C,2H24N4ClCu 
+ 2H^ 326 and [C,2H24N4Cu + 2H^f^ 145; from the loss of C4H9NO, C4H,oN202, 
C8H18N2O2CI and C8H18N2O2CI2 fragments, respectively, which confirm the structure of 
the [C2oH42N602Cu]Cl2 complex. The molecular cation peaks relating to the complexes 
[C2oH42N602Co]Cl2 and [C2oH42N602Ni]Cl2 were not observed. Nevertheless, many 
fragments were observed in each of the specfra to characterize obvious compositions of 
the complexes. Peaks defining [M-2Cr + 2ltf* and (Ci2H24N4ClNi + 6H^ fragments 
were recorded at m/z 23 land 326,respectively for [C2oH42N602Ni]Cl2 complex, while for 
[C2oH42N602Co]Cl2 complcx (C12H24N4CIC0 + 3H^ fragment was observed at m/z 321. 
Other peaks at m/z 143 were ascribed to [C12H24N4C0 + lltf^ and [Ci2H24N4Ni + 
2B^f* fragments for [C2oH42N602Co]Cl2 and [C2oH42N602Ni]Cl2 complex, respectively. 
DNA binding studies 
DNA is the primary intracellular target of antitumour drugs. Interaction of the complexes 
with DNA can induce DNA damage, which leads to blockage of cell division and 
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eventually cell death. Interaction with 5'GMP provides supportive evidence in favor of 
the DNA binding studies. 
Absorption Titration 
The absorption spectral titration of the [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 
complexes with CT DNA was followed by monitoring the absorbance of intraligand 
bands (Figure 35a-b). Any interaction between the complex and the DNA is expected to 
perturb the ligand centered spectral transitions of the complexes. Intensity of the spectral 
band of the complexes at 224 nm and 240 nm were found to increase with the increasing 
concentration of the DNA. The complexes [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 
exhibited hyperchromism of 27.7% and 23.3% when saturated around [DNA]/[complex] 
= 0.75 and 0.58, respectively. The hyperchromic and hypochromic effect are the spectral 
features of DNA concerning its double helix structure. The "hyperchromic effect" which 
results from the structural damage of DNA observed in these complexes is indicative of 
strong binding of the complexes to CT DNA. However, no red shift was observed in the 
absorption traces, which ruled out coordinate covalent binding with N7 base moieties of 
DNA. Complex-interaction occurs with exterior phosphates of DNA primarily via 
electrostatic attraction [213]. Nevertheless, DNA double helix possesses many hydrogen 
bonding sites positioned on the edges of the DNA bases, it is quite probable that the 
coordinated -NH- groups and the dangling -OH groups could form hydrogen bonds with 
the DNA base pairs [214, 215], contributing to the overall hyperchromism. No significant 
change was observed in the absorbance of LF transition of the complexes on the addition 
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of CT DNA revealing that the binding of metal complexes via N7 of guanine is quite 
unlikely. This was evidenced by the UVA'is absorption spectral studies of the complexes 
with 5'GMP. The present ligand framework lacks extended n- systems; the intercalative 
binding mode is therefore, overruled. In order to further compare quantitatively the 
affinity of complexes bound to CT DNA the intrinsic binding constants Kb of the 
complexes were also determined (Figure 35a-b, inset). The binding constants obtained 
for [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 using equation (1) are 2.94.10'' M'' and 
2.71.10'* M ' , respectively, revealing that both the complexes bind strongly to CT DNA 
with almost same affinity. 
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Figure 35a. Absorption spectral traces of [C2oH42N602Co]Cl2 complex in Tris-HCl 
buffer upon addition ofCTDNA. Arrows show the absorbance changes upon increasing 
concentration of the CT DNA. Inset: Plots of [DNAJ/Sa-e/vs [DNA] for the titration of 
CT DNA with [C2oH42N602Co]Ch complex; (*) experimental data points; full lines, 
linear fitting of the data. [C2oH42N602Co]Cl2=1.23. Iff'' M. 
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Figure 35b. Absorption spectral traces of [C2oH42^602Cu]Cl2 complex in Tris-HCl 
buffer upon addition ofCTDNA. Arrows show the absorbance changes upon increasing 
concentration of the CT DNA. Inset: Plots of [DNAJ/Sa-S/vs fDNAJ for the titration of 
CT DNA with [C2oH42N602Cu]Cl2 complex; (^) experimental data points; full lines, 
linear fitting of the data. [C2oH42N602Cu]Cl2=1.33.1(r^ M. 
Interaction studies with 5'GMP 
Interaction of metal complexes with nucleotides is notably important to illustrate the 
binding sequence with DNA at the molecular level. Previously, it has been observed that 
interaction of 5'GMP with Cu^ "^  ion occurs mainly via N7 site [216, 217] while 06 
position is favoured in other early transition metal ions [218]. The absorption spectra of 
complexes [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 on interaction with 5'GMP show 
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hyperchromism in the intraligand bands, with a red shift (bathochromic) of 5 nm for the 
complex [C2oH42N602Cu]Cl2 (Figure 36a-b). However, no distinct spectral changes were 
observed in the LF bands, obscuring the possibility of coordination of the metal ions 
either to N7 or 06 of GMP. The hyperchromicity implies that the interaction between the 
complexes and the GMP is a combination of electrostatic and hydrogen bonding with the 
oxygen of the negatively charged phosphate group to the - NH- of the complex [219] or 
possibly via 06 atom of nucleobase with pendant - OH of the complex. The 
fimctionalized - OH appendage facilitates in carrying the metal ion to the site in the major 
groove. 
0.000^ 
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Figure 36a. Absorption spectral traces of [C2()H42N602Co]Cl2 complex in H2O upon 
addition of 5 'GMP. 
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Figure 36b. Absorption spectral traces of [C2oH42N602Cu]Cl2 complex in H2O upon 
addition of 5'GMP. 
' H and *^P NMR spectroscopic studies with 5'GMP 
The conclusive evidence for the interaction of complexes [C2oH42N602Co]Cl2 and 
[C2oH42N602Cu]Cl2 with 5'GMP was further obtained by ' H NMR and ^'P NMR 
spectroscopy, being most sensitive and a reliable technique (Fig 37a- b). The ' H NMR of 
5'GMP in D2O solvent records the proton resonance of guanine Hg at 8.07 ppm and 
ribose Hi'-Hs' at 3.8-5.8 ppm, respectively. The resonance of 2-NH2 was obscured due to 
the exchange of protons with deuterium solvent. For paramagnetic complexes, the 
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chemical shift of protons adjacent to the metal center will be significantly perturbed and 
there is an apparent line broadening. On interaction of complex with 5'GMP, there is no 
line broadening however, H2' resonance of ribose records an increase in intensity while 
the other peaks of ribose show downfield shift. The G-Hs signal has diminished but does 
not display significant downfield shift (8.07 ppm in free 5'GMP to 8.1 ppm in 
[C2oH42N602Co]Cl2 + 5'GMP bound), which shows non-involvement of N7 position of 
guanine in coordination [220]. These results are also consistent with UVA^is interaction 
studies of complex [C2oH42N602Co]Cl2 with DNA and 5'GMP. ^'P WAR of 5'GMP 
records a signal at 3.65 ppm, which is completely quenched on addition of complex 
[C2oH42N6C)2Co]Cl2 suggcstive of involvement of phosphate moiety via electrostatic 
binding mode. 
Compared with the ' H N M R spectra of 5'GMP and 5'GMP + [C2oH42N6C)2Co]Cl2, the ' H 
NMR spectra of complex [C2oH42N602Cu]Cl2 + 5'GMP displayed remarkable changes. 
The Hg signal due to 5'GMP at 8.07 ppm disappears, while peaks due to Hi'-Hs' showed 
significant line broadening with downfield shifts. These observations depict that the 
complex [C2oH42N6C)2Cu]Cl2 shows tendency for coordination to the N7 position of the 
guanine compared to complex [C2oH42N602Co]Cl2. However, phosphate binding of 
complex [C2oH42N602Cu]Cl2 to 5'GMP cannot be overruled owing to the absence of any 
signal in the ^'P NMR of [C2oH42N602Cu]Cl2 + 5'GMP. These NMR results strongly 
support the phosphate binding of complexes [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 
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Figure 37a. 'HNMR spectra ofi) 5 'GMP and the reaction ofii) [C20H42N6O2C0] Ch and 
[C2oH42N602Cu]Cl2 complexcs (2.5 mM) with 5 'GMP (5 mM) in D2O at 25 V . 
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Figure 37b. ^'PNMR spectrum of 5 'GMP in D2O at 25 "C 
with 5'GMP, and simultaneous coordination of complex [C2oH42N602Cu]Cl2 to the N7 
atom of nucleobase. 
Fluorescence spectroscopic studies 
To exclude the possibility of the intercalative binding mode an ethidium bromide assay 
was carried out. Ethidium bromide is a conjugate planar intercalating molecule emitting 
intense fluorescence when bound to DNA. Decrease in emission intensity results when a 
second DNA binding molecule either replaces EthBr or accepts the excited state electron 
from EthBr [221]. Complexes [C2oH42N602Co]Cl2 and [C20H42N6O2CUICI2 do not display 
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luminescence either alone or in tris buffer. The addition of complex [C2oH42N6C)2Co]Cl2 
and [C2oH42N602Cu]Cl2 to the EthBr-DNA system resulted in the reduction in the 
emission intensity (Figure 38a-b). As complexes [C2oH42N6C)2Co]Cl2 and 
[C2oH42N602Cu]Cl2 bind to DNA primarily via surface binding, they cannot displace the 
strongly DNA bound EthBr. So the observed quenching occurs through the photoelectron 
transfer mechanism [222]. The larger quenching extent of complex [C2oH42N602Cu]Cl2 
than the complex [C2oH42N602Co]Cl2 is expected, as the reduction of the DNA-bound 
complex [C2oH42N602Co]Cl2 (E1/2 = -0.285 V) is more difficult than the complex 
[C2oH42N602Cu]Cl2 (E1/2 = -0.180 V). The relative fluorescence intensity, plotted as a 
function of CT DNA concentration (in terms of [M]/[DNA]) (Insets) is in good 
agreement with the linear Stem-Volmer equation (2), which also proves that the 
complexes bind to DNA. The value of the fluorescence quenching constant Kgv obtained 
as the slope of IQ/I VS r (=[complex]/[DNA]) for complexes [C2oH42N602Co]Cl2 and 
[C2oH42N602Cu]Cl2 are found to be 0.3 and 0.5, respectively. 
Viscosity measurements 
To obtain further support for the binding modes of the complexes with DNA, viscosity 
measurements were carried out as hydrodynamic measurements sensitive to length 
changes are regarded as the most critical tests of a binding model in solution in the 
absence of crystallographic structural data [223]. For DNA binding of a complex, a 
partial or a non-classical mode of binding could bend or kink the DNA helix, reduce its 
effective length and concomitantly its viscosity [224]. 
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Figure 38a. Emission spectra ofEB bound to DNA in the presence of complex in Tris-
HCl buffer. Arrows show the intensity changes upon increasing concentration of the 
[C2oH42N602Co]Cl2 complcx. Inset: Fluorescence quenching curves of DNA bound EB 
[C20H42N6O2C0] CI2 6.6. la^ M-33.0. lOr^ M, fCTDNAJl.ZlOr^M; (^). experimental 
data points; full lines, linear fitting data. 
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Figure 38b. Emission spectra of EB bound to DNA in the presence of complex in Tris-
HCl buffer. Arrows show the intensity changes upon increasing concentration of the 
C20H42N6O2CI2CU complex. Inset: Fluorescence quenching curves of DNA bound EB 
[C20H42N6O2CI2CU] 6.6. W'^M-SS.O. 10'^ H [CT-DNA] 1.2.10-^M; (^). experimental 
data points; full lines, linear fitting data. 
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The effect of the complexes [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 on the viscosity 
of the CT DNA is shown in Figure 39. The relative specific viscosity decreases steadily, 
which imply complexes bind to CT DNA via electrostatic mode [130]. Moreover, the 
decreasing pattern of DNA viscosity occurs probably due to the insertion of the flexible -
OH pendant arm into the DNA helix permitting the hydrogen bond interaction with the 
DNA base pairs [225]. These results are consistent with observed hyperchromic effect of 
[C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 bound to CT DNA. 
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Figure 39. Effects of increasing amount of [C2oH42N60^o]Cl2 complex 
(•),fC2oH42N602CuJ Ch complex (u) on the relative viscosity ofCTDNA at 29 ±0.1 "C. 
[M]= complex concentration 
Cyclic voltammetry 
The cyclic voltammograms of complexes [C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 
were studied in aqueous solution containing 5 mM Tris-HCl/50 mM KCl buffer obtained 
at 0.1 VS" scan rate in the absence and presence of CT DNA. Both the complexes 
display quasi-reversible electrochemical waves for M(II)/M(I) couple. The CV response 
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of the complex [C2oH42N602Co]Cl2 in the absence of DNA (Figure 40a) shows reduction 
of Co(II) to Co(I) at a cathodic peak potential of -0.400 V and the corresponding 
oxidation wave at -0.110 V. The separation of anodic and cathodic peak potentials (AEp) 
is -0.01 V and the ratio of anodic to cathodic peak currents Ipa/Ipc is 0.133, indicating a 
quasi-reversible redox process. The formal potential Em estimated, as the average of Epa 
and Epc is -0.405 V. Complex [C2oH42N602Cu]Cl2 exhibited one quasi-reversible redox 
couple corresponding to the Cu(II)/Cu(I) redox state with Ipa/Ipc =0.322 and the Epc and 
Epa values of -0.440 V and 0.020 V respectively (Figure 40b) For this couple, AEp and 
the formal potential Emare 0.460 V and -0.210 V, respectively. 
Keeping all the parameters constant, quasi-reversibility of the electron transfer was 
maintained in the presence of DNA. Addition of DNA to complex [C2oH42N602Co]Cl2 
and [C2oH42N602Cu]Cl2 resulted in reduction in anodic and cathodic peak currents 
coupled with shifts in Epc, Epa and E1/2 values. However, for complex [C2oH42N602Co]Cl2 
the anodic peak appeared weakly. The apparent reduction in the peak currents of 
[C2oH42N602Co]Cl2 and [C2oH42N602Cu]Cl2 was attributed to the diffusion of the metal 
complexes bound to the large slowly diffusing DNA molecule [126]. The shift in the Em 
values indicates the binding of the complexes [C2oH42N602Co]Cl2 (-0.285 V) and 
[C2oH42N602Cu]Cl2 (-0.180 V) to the DNA surface. These electrochemical results are in 
agreement with the above spectral results supporting that the complexes bind to DNA 
surface involving electrostatic interaction. 
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Figure 40a. Cyclic voltammograms (5 mM Tris-HCl/50 mM KCl buffer, 2f) of 
[C2oH42N602Co]Cl2 complex and complex in absence (Curve a) and presence (curve b) 
ofCTDNA. 
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Figure 40b. Cyclic voltammograms (5 mM Tris-HCl/50 mM KCl buffer. 25^) of 
[C2oH42N602Cu]Cl2 complcx and complex in absence (Curve a) and presence (curve b) 
ofCTDNA. 
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CHAPTER IV 
Synthesis and Characterization of Dinuclear Macrocyclic Cobalt(II), 
Copper(II) and Zinc(II) Complexes derived from 2,2,2,2 -S,S[bis(bis-
N,N-2-thiobenzimidazolyloxalato-l,2-ethane)]: DNA Binding and 
Cleavage Studies 
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CHAPTER IV 
Experimental 
Reagent grade chemicals were used without further purification for all syntheses. 
C0CI2.6H2O, CUCI2.2H2O, ZnCh. K2CO3, KI, 1,2-dibromoethane, diethyloxalate, Tris-
base (Merck), 2-mercaptobenzimidazole (Sigma-Aldrich Chemie), 6X loading dye 
(Fermental Life Science) and supercoiled pBR322 plasmid DNA (Genei) were used as 
received and calf thymus DNA (CT DNA) was obtained from Sigma. Microanalysis 
(%CHN) was performed on a Carlo Erba analyzer model 1108. Molar conductances were 
measured at room temperature with a Digisun electronic conductivity bridge. Infrared 
spectra were collected by using KBr pellets on an Interspec 2020 FT-IR spectrometer. 
Shimadzu UV-1700 PharmaSpec UVA^is specfrophotometer was used to record the 
elecfronic spectra. Data were reported in nm. ' H and '^C spectra were recorded on a 
Bruker DRX-300 specfrometer at 300 MHz. Chemical shifts were reported on the 6 scale 
in parts per million (ppm). The EPR spectrum of the copper complex was acquired on a 
Varian E 112 spectrometer using X-band frequency (9.1GHz) at liquid nifrogen 
temperature in solid state. The electrospray mass spectra were recorded on a Micromass 
Quattro II triple quadrupol mass spectrometer. Emission spectra were determined with a 
Hitachi F-2500 fluorescence spectrophotometer. Cyclic voltammetry was performed on 
CH-instrument electrochemical analyzer. The supporting electrolyte was 0.4 M KNO3 in 
water. All samples were purged with nitrogen prior to measurements at room 
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temperature. A three-electrcxie configuration was used comprised of a Pt micro cylinder 
as a working electrode, Pt wire as auxiliary electrode and an Ag/AgCl electrode as a 
reference electrode. All the experiments involving the interaction of the complexes with 
DNA were conducted in aerated Tris-HCl buffer (0.01 M, pH 7.2). 
The cleavage of supercoiled pBR322 plasmid DNA in absence of activating agents was 
observed using gel electrophoresis. In reactions using supercoiled pBR322 plasmid DNA 
300 ng in Tris-HCl buffer (10 mmol) at pH 7.4 was treated with complex 
[C36H24N8O4S4CI4CU2] (50-250 \iM). The samples were incubated for 1 h at 37 °C. A 
loading buffer containing 25 % bromophenol blue, 0.25 % xylene cyanol, 30 % glycerol 
was added and electrophoresis was carried out at 100 V for 2 h in Tris-HCl buffer using 1 
% agarose gel containing 1.0 ^g/mL ethidium bromide 
The DNA cleavage with added reductant ascorbic acid was monitored as in case of 
cleavage experiment without added reductant using agarose gel electrophoresis. 
Reactions using pBR322 plasmid DNA in Tris-HCl buffer at pH 7.4 was treated with 
complex [C36H24N8O4S4CI4CU2] (50-250 ^mol) and ascorbic acid (10 )imol). The samples 
were incubated for 1 h at 37 °C. The gels were documented and analyzed by UVP gel. 
Synthesis of N^-bis(2-mercaptobenzimidazolyl)oxalate hydrochloride 
C,9H25N405S2Cl3 
The ligand C19H25N4O5S2CI3 was synthesized according to the reported procedure [226] 
as described. To a methanolic solution of 2-mercaptobenzimidazole (5.00 g, 33 mmol), 
diethyl oxalate (2.26 mL, 16 mmol) was added in a 2:1 molar ratio. The solution was 
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heated under reflux for ca. 1 h. After cooling, concentrated. HCl (6 mL) was added 
dropwise with stirring. The cream crystalline product formed, was filtered off, washed 
thoroughly with hexane and dried in vacuo. 
Synthesis of 2,2,2',2'-S,S[ bis(bis-N,N-2-thiobenziinidazolyI oxalato-1,2- ethane)] 
C38H29N9O5S4 
A mixture of C19H25N4O5S2CI3, (4.62 g, 10 mmol) 1,2-dibromoethane (0.86 mL, 10 
mmol), anhydrous K2CO3 (1.38 g, 10 mmol) and KI in acetonitrile was stirred for ca. 24 
h at 35±5 °C. The reaction mixture was poured into water, made alkaline with NaOH 
solution. The TLC pure compound was isolated, washed with H2O and dried in vacuo. 
Synthesis of 2,2,2', 2'-S,S[bis(bis-N,N-2-thiobenzimidazoIyloxalato-l,2-
ethane)Cobalt(II)lchloride[C36H24N804S4Co2]Cl4 
The ligand C38H29N9O5S4 (1.9 g, 25 mmol) and C0CI2.6H2O (1.36 g, 50 mmol) were 
dissolved in 20 mL MeOH. The solution was heated to reflux for 24 h, resulting in a clear 
blue solution. Slow evaporation of the solution afforded a deep blue TLC pure crystalline 
compound. 
Synthesis of Dichloro-2,2,2%2'-S,S[bis(bis-N,N-2-thiobenziniidazolyloxaIato-l,2-
ethane)Copper(II)] [C36H24N8O4S4CI4CU2] 
To a methanolic solution of ligand C3gH29N905S4 (1.9 g, 25 mmol), CUCI2.2H2O (0.85 g, 
50 mmol) in 50 mL was added and heated to reflux for 24 h. On slow evaporation of the 
reaction mixture a green compound obtained was filtered and dried in vacuo. 
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Synthesis of Dichloro-2^^',2'-S,S[bis(bis-N;M-2-thiobenzimidazolyloxalato-U-
ethane)Ziiic(II)] [C36H24N804S4Cl4Zn2]. 
This complex was synthesized by a similar method as described for 
[C36H24N804S4Co2]Cl4 using anhydrous ZnCh (0.68 g, 50 mmol). The cream coloured 
complex obtained was isolated and dried in vacuo. 
Results and discussion 
The ligand C38H29N9O5S4 and its metal complexes [C36H24N804S4Co2]Cl4, 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] were synthesized by a procedure as 
illustrated in Scheme 2. Formulations of the ligand and the complexes were verified by 
elemental analysis, molar conductivity as well as by UVA^is, mass and NMR 
spectroscopy. Molar conductance measurement of the complexes in DMSO corresponds 
to the 1:4 electrolytic nature for complex [C36H24N804S4Co2]Cl4 while complexes 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] behave as non-electrolytes. Evidently, 
in complexes [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] the metal ions are 
hexacoordinated surrounded by O2S2CI2 environment, adopting an octahedral geometry, 
while in complex [C36H24N804S4Co2]Cl4 the Co(II) ions are in tetrahedral environment 
with O2S2 donor set, confirmed by UVA^is and mass spectral data. Complexes 
[C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] and ligands 
C19H25N4O5S2CI3 and C38H29N9O5S4 were soluble in DMF, DMSO and MeOH, 
respectively. 
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N. 
I T >^—SH + C2H5OOCCOOC2H5 
N / \ N 
N ^ ^ N 
MeOH 
KjCOj 
KI 
Cone. HCl 
•N 
N ^ O 
N ^ O 
/>—SH 
N 
CH3CN 
1,2-Dibromoethane 
CI N 
M = Cu(II). Zn(II) 
Scheme 2. Synthetic route and proposed structures of the ligands C19H25N4OSS2CIS and 
C3SH29N9OSS4 and complexes fC3^24^x0484002] CI4, [C36H24NHO4S4CI4CU2] and 
fC36H24N,04S4Cl4Zn2j. 
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The important properties and physical data of the ligands and the metal complexes are 
given in Table 5. Energy minimized structvire using CS Chem Draw 3D Pro 5.0 as shown 
in Figure 41 validated the proposed structures. DNA binding studies were performed with 
[C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] complexes. 
Figure 41. Three dimensional molecular model of [C36H24M804S4Co2]Cl4 complex; 
Colour Scheme Co" dark blue; N light blue; S yellow; O red; C gray. 
Infrared Spectra 
The IR spectrum of the ligand C19H25N4O5S2CI3 exhibited a characteristic band at 2368 
cm'' attributed to the u(S-H) vibrations [226], indicating that the thiol proton remains 
attached to the sulphur atom. Howeve?, the absence: of u(N-H) stretching band at ~ 
3400cm" [227] unplies its deprotonation and subsequent ligand formation with 
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diethyloxalate. The presence of an intense o(C=0) stretching absorption detected at 1625 
cm' confirms the bridging of the two imidazole rings [228]. Two medium intensity bands 
at 1523 cm' and 1353 cm"' were assigned to the o(C=N) and u(C-N), respectively [229]. 
The IR spectrum of the ligand C38H29N9O5S4 was quite similar to C19H25N4O5S2CI3 
except for the missing peak at 2368 cm"' due to the -SH group. The deprotonation of 
thiol groups was also inferred from the presence of a broad band at ca. 2853 cm' 
belonging to the u(CH2) of the aliphatic chain. Additionally, the pure characteristic u(C-
H) modes of the ring residues in C19H25N4O5S2CI3 and C38H29N9O5S4 were observed in 
the wave regions at 3100 cm"'. The IR spectra of the complexes [C36H24N804S4Co2]Cl4, 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] reveal slight but specific differences 
from the spectra of free ligands. On complexation, the shifting of the ligand u(C=0) and 
u(C-S) bands towards the lower side suggests the involvement of oxygen and sulphur 
atoms in coordination. Of particular interest is the lower frequency region, characteristic 
for the metal-chloride and metal-oxygen stretching vibrations. Complexes 
[C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] display metal-
oxygen bands at 493-509 cm"'. The appearance of a band at ~ 455 cm"' region in 
complexes [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] supports the formation of 
metal-chloride bonds while its absence in the IR spectrum of [C36H24N804S4Co2]Cl4 
indicates that the chloride ions do not participate in coordination and behave as 
counterions. This was also supported by the ESI MS and conductivity measurements 
(Table 6). 
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NMR Spectra 
The formation of new macrocyclic complexes were also ascertained by ' H and '^ C NMR 
spectra of the ligand C19H25N4O5S2CI3, C38H29N90$S4 and complex 
[C36H24N804S4Cl4Zn2]. The signal due to the - SH functionality appearing at 2.95 ppm in 
the free ligand spectrum of C19H25N4O5S2CI3 was missing both in the ligand 
C38H29N9O5S4 and complex [C36H24N804S4Cl4Zn2] [230]. Absence of the characteristic -
NH proton signal of the imidazole ring at 12.00— 14.00 ppm corresponds to the 
deprotonation of the -iSfH group. The observation of a singlet for methylene protons at 
2.75-2.80 ppm [231] and a multiplet for the benzimidazole protons in the range 7.15-7.69 
ppm indicated the equivalence of the two halves of the ligand C38H29N9O5S4. Compared 
with the free ligand, complex [C36H24Ng04S4Cl4Zn2] showed proton signals at nearly 
identical positions (Table 7). The '^C NMR spectra of the ligands C19H25N4O5S2CI3 and 
C38H29N9O5S4 exhibited the resonances due to the carbonyl -C=0 and ring carbon atoms 
of the imidazole moiety at 151.24—164.27 ppm and at 112.96-139.25 ppm, respectively. 
Signals at 39.5 ppm were ascribed to the S-CH2-CH2-S [232] carbons of the ligand 
C38H29N9O5S4. Complex [C36H24N804S4Cl4Zn2] displayed spectral pattern similar to that 
of the ligands except downfield chemical shifts of carbon signals. The carbonyl signal 
was desheilded in the spectra of the metal complex, which appeared at 164.27 ppm in 
comparison to 151.24 ppm in C38H29N9O5S4, inferring coordination through the oxygen 
atom of the ligand. Significant chemical shift was also observed for -S-CH2- resonances, 
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which implies coordination via sulphur atoms. These observed spectral features 
conformed to the proposed macrocyclic structure (Table 8). 
Mass spectra 
The ESI MS spectra of the ligand C19H25N4O5S2CI3, C38H29N9O5S4 and the complex 
[C36H24N804S4Co2]Cl4 wcrc obtained in the acetonitrile solutions. The spectrum of the 
ligand C19H25N4O5S2CI3 shows peaks at m/z 429 and 494 were assigned to the 
(Ci6H,2N402S2Cl2+2ir) and (C17H17N4O3S2CI3 +H^ compounds, respectively. For the 
ligand C36H24N8O4S4 peaks centered at m/z 817 and 775 corresponded to the 
(C38H29N905S4-2H^ and (C36H26N805S4.H20-3H^ species, respectively. The ESI MS 
spectrum of the complex [C36H24N804S4Co2]Cl4 shows molecular ion peak at m/z 1019. 
Peaks at m/z 981, 478, 222 and 224 correspond to the ion peaks resulting from the 
successive expulsion of the chloride ions from the complex entity. This implies that the 
chloride ions were not coordinated to the Cobalt ion. 
EPR spectrum 
The solid state X-band EPR spectrum of the complex [C36H24N8O4S4CI4CU2] acquired at 
LNT imder the magnetic field strength 3000±1000 guass with tetracyanoethylene 
(TCNE) as field marker (g = 2.0027) showed an anisotropic spectrum, exhibiting both 
parallel and perpendicular g values. The EPR spectrum of complex 
[C36H24N8O4S4CI4CU2] consists of a very broad axial symmetrical line shape with g|| = 
2.16, gi = 2.08 values and gav - 2.106 computed from the formula gav^  = g\\' + 2 gi^ / 3, 
suggesting an octahedral geometry. The trend g||> gx>ge (2.0023) revealed that the 
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unpaired electron was located in the dx^ .y'^  orbital of the Cu" ions characteristic of axial 
symmetry [233]. The parameter G = ig[\-2)/ (gi-2), which measure the exchange 
interaction between the metal center in a polycrystalline solid. According to Hathaway 
and Billing [234] G>4 indicate negligible exchange interaction in the solid complex. For 
the Cu(II) complex G <4 indicates considerable exchange interaction in the complex. 
Electronic spectra 
The electronic spectra of the ligands C19H25N4O5S2CI3, C38H29N9O5S4 and complexes 
[C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] were recorded 
in DMSO at room temperature. The UV region of the electronic spectra of the ligands, 
both free and in the coordinated form was dominated by a pair of bands, one intense and 
a narrow band at 270 - 290 nm and a second less intense band around 242 - 247 nm. The 
low energy UV band has been assigned to an intraligand n —• n* transition of the 
benzimidazolyl groups and the high energy UV band was ascribed to intraligand charge 
transfer transitions. In the visible region, complex [C36H24N804S4Co2]CU displays two 
bands, one low at 617 nm and a high at 680 nm assigned to ''A2 • ' 'T] transition, 
typical for tetrahedral Co(II) complexes [235]. The high value of the molar extinction 
coefficient and the blue colour of the Co(II) complex, also authenticate tetrahedral 
stereochemistry. On the other hand complex [C36H24N8O4S4CI4CU2] showed a band with 
low extinction coefficient at 800 nm due to ^Big ^^Aig transition [236] supporting an 
octahedral geometry around Cu(II) metal ion. 
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DNA binding studies 
Absorption spectral studies 
The binding of the metal complexes to DNA helix is often characterized through 
absorption spectral titration, followed by the changes in the absorbance and shift in the 
wavelength. The absorption spectra of [Cj6H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] 
and [C36H24N804S4Cl4Zn2] in the absence and presence of CT DNA are illustrated in 
Figure 42a-c, respectively. Upon the addition of CT DNA to [C36H24N804S4Co2]Cl4, 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2], interesting changes in the 
absorbances of the intraligand absorption bands of the complexes were observed — 
hyperchromism for [C36H24N804S4Co2]Cl4 and hypochromism for [C36H24N8O4S4CI4CU2] 
and [C36H24N804S4Cl4Zn2]. Hyperchromism and hypochromism are the spectral changes 
typical of a metal complex association with the DNA helix [237, 238]. The 
hypochromicity, characteristic of intercalation [239] has been usually attributed to the 
interaction between the electronic states of the compound chromophores and those of the 
DNA bases [240], while the red shift has been associated with the decrease in the energy 
gap between the highest and the lowest molecular orbitals (HUMO and LUMO) after 
binding of the complex to DNA [241]. The observed hyporchromism for 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] unambiguously revealed the active 
participation of bzim moieties in associating with the DNA [242]. However, the lack of 
red shift suggests that the binding mode of both [C36H24N8O4S4CI4CU2] and 
[C36H24N804S4Cl4Zn2] was not classical intercalation. Because of the bulky structure of 
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the complexes, the bzim rings cannot completely intercalate. When one of the four bzim 
rings inserts into the helix, the other rings extends away from the plane due to the 
stereochemistry effect and hence decreasing the effective area of overlap. Interestingly, 
the complex [C36H24N804S4Co2]Cl4, inspite of containing bzim rings exhibits a 
hyperchromism, suggestive of electrostatic binding. Due to electrostatic binding on the 
DNA surface, it appears to imdergo distortion in the coordination sphere resulting in the 
enhanced absorption intensity of the intraligand bands. Similar reports were observed for 
DNA binding studies of ruthenium complexes derived from tetradentate 
bis(benzimidazol-2-yl)dithioether ligands [243]. Therefore, the observed spectral changes 
were rationalized in terms of partial intercalation and electrostatic binding. To further 
illustrate the DNA binding sfrength, the intrinsic binding constant Kb were determined by 
equation 1 for complexes [C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and 
' [C36H24N804S4Cl4Zn2] which were found to be 16.6 . lO'* M"', 4,25. 10'* M"' and 3.0 . 10* 
M"', respectively. The binding constants of these complexes were lower in comparison to 
those observed for typical classical intercalators [244]. The diminution of the intrinsic 
binding constants could be explained by the steric constraints imposed by the ligand 
framework and thus encouraging a partial intercalation binding mode for the complexes. 
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Figure 42a. Absorption spectral traces of complex fC36H24Ns04S4CoJCl4 in Tris-HCl 
buffer upon addition ofCTDNA. Inset: Plots of[DNA]/ Sa-e/vs [DNA] for the titration of 
CT DNA with complex fC36H24N804S4Co2]Cl4 (m), experimental data points; full line, 
linear fit of the data. [CompIex]= 0.33 • 10^ M, [DNA] = 0.86 - 4.30- 10"^  M. 
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Figure 42b. Absorption spectral traces of complex [€3^24^804S^l/Zu2} in Tris-HCl 
buffer upon addition ofCTDNA. Inset: Plots of [DNA]/ Sa-C/vs [DNA] for the titration of 
CT DNA with complex [C36H24N8O4S4CI4CU2] (m), experimental data points; full line, 
linear fit of the data. [Complex]= 0.33 • Iff" M, [DNA] = 0.86 — 4.30- Iff^ M. 
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Figure 42c. Absorption spectral traces of complex fC36H24Ns04S4Cl4Zn2] in Tris-HCl 
buffer upon addition ofCTDNA. Inset: Plots of[DNA]/ Sa-S/vs [DNA] for the titration of 
CT DNA with complex [Ci^24Ns,OS4^U'Z.n2j (m), experimental data points; full line, 
linear fit of the data. [Complex] = 0.66- ICT^M, [DNA] = 0.44-2.21- W^M. 
Fluorescence studies 
Upon excitation at % —• n* transitions either in DMSO or in presence of CT DNA, 
complexes [C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] 
cannot emit luminescence. Hence, steady state competitive binding studies of the three 
complexes were monitored by a fluorescent EthBr displacement assay. EthBr, a planar 
aromatic heterocyclic dye intercalates non-specifically into the DNA, which causes it to 
fluoresce strongly [245]. 
EthBr(weakfluorescent)+DNA(non-fluorescent) '-* ^ EthBr-DNA(strong fluorescent) 
Competitive binding of second DNA binding macromolecule results in the displacement 
of bound EthBr and a decrease in the fluorescence intensity, furnishing indirect evidence 
for the DNA binding mode. The emission spectra of EthBr bound DNA in the absence 
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and presence of increasing amounts of complex [C36H24Ng04S4Co2]Cl4, 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] are given in Figure 43a-c. The 
emission intensity of DNA-EthBr system (Kem =590 nm) decreases appreciably, whicli 
indicated tiiat the compounds could replace EthBr from the DNA-EthBr system. Such a 
characteristic change is often observed in intercalative binding modes [246]. The 
quenching plots (inset) followed the linear Stem-Volmer relationship (equation 2). 
The Stem -Volmer quenching constant Ksv values for complexes C36H24Ng04S4Co2]Cl4, 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] obtained from equation 2 were found 
to be 0.04,0.26 and 0.06, respectively. 
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Figure 43a. Emission spectra of EthBr bound to DNA in the presence of complex 
[C36H24N8O4S4C0JCI4 in Tris-HCl buffer. Arrows indicate the intensity changes upon 
increasing concentration of the complex. Inset: Fluorescence quenching curve of DNA 
bound EthBr with complex (*), experimental data points; full lines, linear fit of the data. 
[Complex] = 0.33 -1.66- lO'^M, [DNA] = 0.66 • Kf^M; A„ = 510 nm. 
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Figure 43b. Emission spectra of EthBr bound to DMA in the presence of complex 
[C36H24N8O4S4CI4CU2J in Tris-HCl buffer. Arrows indicate the intensity changes upon 
increasing concentration of the complexes. Inset: Fluorescence quenching curve ofDNA 
bound EthBr with complex (^), experimental data points; full lines, linear fit of the data. 
[Complex] ^0.33- 1.66- 10'^M, [DMA] = 0.66- KT^M; Xex = 510 nm. 
Wavelength (nm) 
Figure 43c. Emission spectra of EthBr bound to DNA in the presence of complex 
[C36H24N804S4Cl4Zn2] in Tris-HCl buffer. Arrows indicate the intensity changes upon 
increasing concentration of the complexes. Inset: Fluorescence quenching curve of DNA 
bound EthBr with complex (^), experimental data points; full lines, linear fit of the data. 
[Complex] = 0.66-2.66- 10"'M, [DNA] = 0.33 • Iff^M; k^ = 510 nm. 
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The effect of the complexes C36H24N804S4Co2]Cl4, [C36H24N8O4S4CI4CU2] and 
[C36H24N804S4Cl4Zn2] on the fluorescence intensity of EthBr was also investigated in 
presence of increasing amounts of DNA. The fluorescence intensity of EthBr has a 
gradual enhancement with the addition of DNA in the absence and presence of metal 
complexes. Fluorescence Scatchard plots [247] for the binding of EthBr to DNA in 
presence of metal complexes (Figure 44) were obtained from equation; 
rEB/CEB,f=(n-rEB)[KEB/l+KM] (5) 
where res is the ratio of bound EthBr to total nucleotide concentration; CEB,ft 
concentration of free EthBr; n, maximum value of TEB, KEB, and KM, intrinsic binding 
constant for EthBr and metal complexes to DNA, respectively, and CM,f, concentration of 
free metal complex. Using fluorescence to obtain rEB, binding isotherms were 
constructed. With the addition of the complexes, the slope that is Kobs decreases with the 
increase in the concentration of the complex indicating inhibition of EthBr binding 
(Figure. 45). From the above equation (5) we obtain the relationship; 
Kobs = [KEB/l+KM] (6) 
The reciprocal of equation (6) produces a straight line equation; 
1/Kobs = (KM /KEB) CM,f, + 1/ KEB- (7) 
The concentrations of free complexes were approximated from the following equation; 
rM = n - rEB - TEB/ KEB CEB (8) 
CM,f = CM - TM CDNA (9) 
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0.038 0.04S 0.054 0.062 0.07 0.078 0.086 0.094 
Figure 44. Scatchard plots for the binding ofEthBr to DMA in presence of a) 0.3 • 10'''M 
b) 1.33 • / O ' V c) 3.30 • l(fM of the representative [C36H24N8O4S4C0ZICU complex; 
[EthBr] "= 0.66 • lO^M; (^), experimental data points; full lines, linear fit of the data. 
Where TM is the ratio of bound complex to total DNA concentration, CM,f and CM are 
concentrations of free and total metal complex, respectively. Replots of Kobs gave the 
approximate binding constants of the complexes [C36H24N804S4Co2]Cl4 
[C36H24Ng04S4CUCu2] and [C36H24Ng04S4 CI4 Zn2], which were calculated to be 2.49 . 
10\ 1.04. 10" and 1.85 . 10\ respectively. 
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Figure 45. Replot of observed binding constant of EthBr to DMA for a) 
fC36ff24N804S4Co2jCl4 complex b) [C36H24N8O4S4CI4CU2] complex and c) 
[C36H24N8O4S4 CI4 ZnJ complex: (^,m), experimental data points; full lines, linear fit of 
the data. 
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DNA Cleavage activity 
The chemical nuclease like activity of the [C36H24N8O4S4CI4CU2] complex, has been 
investigated by agarose gel electrophoresis using supercoiled pBR322 plasmid DNA as a 
substrate. The pBR322 DNA was mixed with different concentrations of 
[C36H24N8O4S4CI4CU2] in Tris HCl buffer in the absence and presence of reductant 
ascorbic acid and mixtures were incubated at 37 °C for Ih. Control experiments using 
only complex or ascorbic acid failed to show any apparent cleavage activity, hi the 
absence of ascorbic acid, pBR322 plasmid DNA was converted from SC (form I) to NC 
(form II), (Figure 46a) revealing the efficient cleavage like activity and at higher 
concentrations of complex [C36H24N8O4S4CI4CU2], increased band intensities were 
observed. Since Cu(II) complexes are catalytically active in the oxidation of ascorbic acid 
by dioxygen involving Cu(I) intermediate species, we have examined the cleavage like 
activity of [C36H24Ng04S4Cl4Cu2] in presence of ascorbic acid at increasing concentration 
of the complex. There was complete conversion of SC form I to nicked DNA form (II) 
with almost disappearance of form (III). The bands are more intensified in presence of 
ascorbic acid than in the absence of ascorbic acid as seen from Figure 46b. The intense 
nuclease activity was apparently caused by enhanced stabilization of Cu(I) species 
formed upon its reduction by ascorbic acid. This supports oxidative cleavage mechanism 
of [C36H24N8O4S4CI4CU2] where Cu(II) complex is first reduced by ascorbic acid to form 
the Cu(I) species, which then binds to DNA forming a Cu(I)complex-DNA adduct. This 
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adduct then reacts with dioxygen to form a peroxodicopper (II) derivative which could 
generate active oxygen species required for cleavage [248]. 
Viscosity studies 
To further explore the interaction properties between the metal complexes and the DNA, 
the relative specific viscosity of DNA was examined by varying the concentration of the 
added metal complexes. Measuring the viscosity of DNA is a classical technique used to 
analyze the DNA binding mode in solution [249]. Hydrodynamic measurements i.e. 
viscosity, sedimentation, rotational diffusion etc sensitive to molecular lengths provide 
strong evidences for the DNA-binding modes, especially in absence of crystallographic 
and NMR structural data [250]. A classical intercalation model results in the lengthening 
of the DNA helix as the base pairs are separated to accommodate the binding molecule, 
leading to an increase in the DNA viscosity. In contrast, partial intercalators as well as 
NC 
sc 
Figure 46a. Gel electrophoresis diagram showing cleavage ofpBR322 supercoiled DNA 
(300 ng) by [C36H24N8O4S4CI4CU2] complex, in absence of ascorbic acid; 250 fiM 
[C36H24N8O4S4CI4CU2] + DNA, (lane 1), 200 juM [C36H24N8O4S4CI4CU2] + DNA (lane 
2), 150 fiM [C36H24N804S4Cl4Cu2]+ DNA (lane 3), 100 fiM [C36H24N8O4S4CI4CU2] + 
DNA (lane 4) and 50 fiM [C36H24N8O4S4CI4CU2] + DNA (lane 5), control DNA (lane 6). 
lUJ 
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Figure 46b. Gel electrophoresis diagram showing cleavage ofpBR322 supercoiled DNA 
(300 ng) by [C36H24N8O4S4CI4CU2] complex, in presence of ascorbic acid (10 fxM) 250 
liM by [C36H24N8O4S4CI4CUZJ + DNA, (lane 1), 200 juM by [C36H24N8O4S4CI4CU2J + 
DNA (lane 2), 150 fiM by [C36H24N804S4Cl4Cu2]+DNA (lane 3), 100 fiM by 
[C36H24N8O4S4CI4CU2] + DNA (lane 4) and 50 /iM by fC36H24N804S4Cl4Cu2j+DNA (lane 
5), control DNA (lane 6). 
covalent binders could bend or kink DNA helix, reduce its effective length and in turn its 
viscosity [251, 252]. Figure 47 depicts the effect of complexes C36H24N804S4Co2]Cl4, 
[C36H24N8O4S4CI4CU2] and [C36H24N804S4Cl4Zn2] on the DNA viscosity. The plot 
reveals that the relative solution viscosity decreased with increasing concentration of the 
complexes, indicating that the DNA becomes more compact, resulting in DNA 
aggregation. The aggregation reduces the number of independently moving DNA 
molecules in solution and hence leads to a decrease in viscosity. These results support 
that complexes bind to CT-DNA by partial intercalation [253]. Further, due to the bulky 
structure of the complexes, they would act as a wedge to pry apart one side of a base pair 
stack but not fully separate the stack as required by the classical intercalation model. 
.^ 0.4 
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Figure 47. Effect of increasing amount of [C36H24N804S4Co2]Cl4 complex 
(m),[C36H24N804S4Cl4CuJ complex (A) and [CiJiiitNsOSACUZnz} complex (^) on the 
relative viscosity ofCT-DNA at 29 ±0.1 °C. [DMA] = 0.25 • la" M, [M] = 0.05 - 0.25-
Cyclic voltammetry 
CV is an electroanalytical technique used to study the mechanistic behaviour of redox 
systems of new metal complexes. Due to the resemblance between the electrochemical 
and biological reactions, CV provides a useful complement to study the binding of metal 
complexes to DNA, in addition to other spectroscopic methods of investigation. The 
cyclic voltammograms (Figure 48,49) of the complexes [C36H24Ng04S4Co2]Cl4 and 
[C36H24N8O4S4CI4CU2] show cathodic and anodic peaks due to the reduction of M " and 
its subsequent oxidation. In absence of CT DNA, complex [C36H24N804S4Co2]CU 
exhibits a quasireversible redox wave for a one-electron transfer process corresponding to 
the Co'VCo' redox couple with an anodic peak potential Epa of-0.27V and a cathodic 
peak potential of-0.35V, respectively. The formal potential Em taken as an average of 
anodic and cathodic peak values is -0.310 V and the corresponding AEp value was 0.08V. 
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No appreciable change was observed at different scan rates. In presence of CT DNA, 
there is a shift in AEp value (0.16V) as well as in the E\n value (-0.28V), indicative of 
strong binding of the complex to CT DNA. The cyclic voltammogram of complex 
[C36H24N8O4S4CI4CU2] also reveals a one electron quasireversible behaviour with E1/2 = -
0.33V and AEp= 0.16V (Epa= -0.25V and Epc= -0.41V) [254]. In presence of DNA 
reversibility of the electron transfer was maintained with a significant shift in AEp value 
(0.15V) as well as in E1/2 value (-0.375V). In addition to the changes in the formal 
potential, the peak currents in the cyclic voltammograms of both the complexes 
decreased than those in absence of DNA, indicating a strong binding of the complexes 
[C36H24N804S4Co2]Cl4 and [C36H24N8O4S4CI4CU2] with DNA. 
Figure 48. Cyclic voltammograms at a scan rate 0.2 Vs'' in DMSO/H2O (5:95) a) free 
[C36H24Ns04S4Co2]Cl4 compicx b) [C36H24N8O4S4C0JCI4 complex in presence of CT 
DNA. 
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Figure 49. Cyclic voltammograms at a scan rate 0.2 Vs'' in DMSO/H2O (5:95) a) free 
[C36H24N8O4S4CI4CU2J complex b) [C36H24N8O4S4CI4CU2] complex in presence ofCT 
DNA. 
From reversible redox reactions of the free and bound species, the corresponding 
equilibrium constants for binding of each oxidation state to DNA can be obtained from 
the Nemst equation. 
Eb°-Ef°=0.0591og(KK/K2+) 
Where Eb° and Ef° are the formal potentials of M"/ M ' couple, in the free and bound 
forms respectively and Ki+and K2+ are the corresponding binding constants for +1 and 
+2 species to DNA. K1+/K2+ has been determined using the above equation and found to 
be 3.22 and 5.76 for complexes [C36H24N804S4Co2]Cl4 and [C36H24N8O4S4CI4CU2], 
whose potential shifts are 0.03V and 0.045V, respectively. 
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CHAPTER V 
Synthesis and Biophysical Studies of Bis-macrocyclic cobalt/copper (II) 
Complexes having Pyridine Spacer with CT DNA and 5' GMP 
I l l 
CHAPTER V 
Experimental 
Reagent grade Chemicals and solvents were used without further purification. 
C0CI2.2H2O, NiCl2.6H20, CUCI2.2H2O, Tris-base (Merck), l,8-diamino-3,6-diazaoctane 
(Fluka), formaldehyde, perchloric acid (BDH) and 2,6-diaminopyridine (Lancaster) were 
used as received. Calf thymus DNA (CT DNA) and guanosine-5'-monophosphate 
disodium salt (5'GMP) were purchased from Sigma chemical Co. and Fluka, 
respectively. 
Molar conductances X^ (in il'cm^ mol"'): at 25 °C, Digisun electronic conductivity 
bridge. UVA'is Spectra: USB 2000 Ocean Optics spectrometer; H2O solns. A^nax in nm. 
IR Spectra: KBr pellets, Interspec 2020 FT-IR spectrometer; in cm*'. '^ C and ' H N M R 
Spectra: at 75 MHz and 300 MHz respectively; Bruker-DRX-300 spectrometer; 5 in ppm. 
EPR Spectra: Varian-E-112 spectrometer; at the X-band frequency (9.1GHz) at liq. N2 
temp. Elemental analyses: Carlo Erba analyzer model 1108. Electrospray mass spectra; 
Micromass Quattro II triple quadrupol mass spectrometer. 
All the experiments involving interaction of the complex with CT DNA were performed 
in twice distilled buffer containing tris(hydroxymethyl)-aminomethane (Tris, 0.01 M) and 
adjusted to pH 7.5 with hydrochloric acid. Solution of 5'GMP was prepared in double 
distilled water. Absorption spectral titration experiments at constant concentration of the 
complexes [6.6 x 10'^  M] while varying the CT DNA concentration and 5'GMP were 
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performed on USB 2000 Ocean Optics spectrometer and UV-1700 PharmaSpec UV-Vis 
spectrophotometer (Shimadzu) respectively. Cyclic voltammetric studies were paformed 
on a CH Instrument Electrochemical analyzer in a single compartmental cell with 0.4 M 
KNO3 as a supporting electrolyte. A three-electrode configuration was used comprising 
of a Pt wire as auxiliary electrode, platinum micro cylinder as working electrode and 
Ag/AgCl as the reference electrode. Electrochemical measurements were made under a 
dinitrogen atmosphere. All electrochemical data were collected at 25°C 
and are uncorrected for junction potentials. 
Synthesis of 2,6-bis[l,3,6,9,12-pentaazacyclotridecane pyridine cobalt(II)] 
perchlorate [C2iH43N„Co2l (€104)4 
To a stirred methanol solution of C0CI2.2H2O (2.37 g, 10 mmol) were slowly added 1,8-
diamino-3,6-diazaoctane (1.49 mL, 10 mmol), 37% formaldehyde (3.03 mL, 20 mmol) 
and 2,6- diaminopyridine (0.54 g, 5 mmol). The resulting mixture was refluxed for ca. 24 
h until a dark reddish brown solution appeared. This solution was cooled and filtered 
under vacuum. Excess perchloric acid in methanol was added to the filtrate and left to 
stand over night. Reddish brown solid product was filtered off, thoroughly washed with 
methanol and dried in vacuo over fused CaCl2. 
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Synthesis of 2,6-bis[l,3,6,9,12-pentaazacyclotridecane pyridine nickel(II)] 
perchlorate [CiiajaNnNiz] (€104)4 
This dark brown coloured complex was synthesized by a procedure similar to that 
described for [C2iH43N,iCo2] (004)4 using NiCh.eHzO (2.37 g, 10 mmol). 
Synthesis of 2,6-bis[l,3,6,9,12-pentaazacyclotridecane pyridine copper(II)] 
perchlorate [C21H43N11CU2I (€104)4 
This light brownish complex was obtained by the method analogous to that for 
[C2iH43NnCo2] (C104)4 using CUCI2.2H2O (1.70 g, 10 mmol). 
Results and discussion 
The new bis-macrocyclic complexes [C2iH43NnCo2](C104)4, [C2iH43NiiNi2](C104)4 and 
[C2iH43NiiCu2](C104)4 have been synthesized by the template condensation reaction of 
l,8-diamino-3,6-diazaoctane, formaldehyde and 2,6-diaminopyridine with Co(II), Ni(II) 
and Cu(II) chlorides, respectively. These complexes were isolated by the addition of 
perchloric acid in methanol as depicted in Scheme 3. These complexes are stable at room 
temperature and are soluble in polar solvents such as wato", DMF and DMSO but 
insoluble in methanol and diethylether. The values of molar conductance measured in 
water indicate that the complexes are 1:4 electrolytes. Analytical data were consistent 
with the proposed formulation of the bis-macrocyclic complexes. DNA binding studies 
were performed with [C2iH43NiiCo2](C104)4 and [C21H43N11CU2](€104)4 complexes. The 
analogous nickel complex was synthesized only for NMR studies. The important 
properties and physical data of the complexes are given in Table 9. 
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% ^ ^ 
NH, H,N 
HCIO4 
NH, 
+ MCI2 + HCHO + \ //^ 
NH, 
.4CIO4 
M = Co(Il), Ni(II) &Cu(II) 
Scheme 3. Synthetic route for the bis-macrocyclic complexes [C2iH^ 
[C2,H43N„Co2] (004)4 and fC2iH43N„Cu2](C104)4. 
'104)4. 
Infrared spectra 
The solid-state IR spectra of the bis-macrocyclic complexes [C2iH43NiiCo2](CI04)4, 
[C2iH43N|iNi2](C104)4 and [C2iH43NiiCu2](CI04)4 exhibit peak at 1558-1650 cm' and a 
sharp peak at 1462-1505 cm"' attributed to the azomethine u(C=N) and u(C>=C) 
stretching modes, [255,256] respectively indicating the presence of pyridine spacer 
moiety in the complexes. The absence of characteristic D(NH2) vibration [257] at 3400 
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cm"' supports the deprotonation of the amine groups and the formation of the macrocyclic 
framework via condensation with formaldehyde. The bands observed in the range 1538-
1550 cm"' corresponding to \)(C—N) confirm the macrocyclic structure of complexes. 
Additionally, broad bands at 3200-3250 cm' were ascribed to the stretching vibration of 
v(NH) of the (NH-CH2-CH2-NH) linkage [258]. Other diagnostic bands of medium 
intensity at 2769-2781 cm"' and 1300-1400 cm"' were assigned to C—H stretching and 
bending vibrational modes, respectively [259]. The bands in the region 480—513 cm"' 
were ascribed to the u(M—N) stretching vibrations. The spectra also display strong 
absorption bands near 1000 cm"' (antisymmetric stretch) and sharp bands at 625—633 cm" 
' (antisymmetric bend) due to the uncoordinated C104~ anions [260-262] (Table 10). 
NMR spectral studies 
To further elucidate the structure of the bis-macrocyclic complexes, the diamagnetic 
complex [C2iH43NiiNi2](C104)4 was characterized by ' H and '^ C NMR spectroscopy, 
showing characteristic aliphatic and aromatic signals with chemical shifts in accordance 
with the proposed structure (Table 11). The aromatic region of the spectrum of 
[C2iH43NiiNi2](C104)4 was consistent with the presence of a doublet at 7.69-8.02 ppm 
and a well-resolved triplet at 6.97-7.31 ppm due to equivalent and non-equivalent 
hydrogens from the pyridine spacer [263]. Comparison of ' H NMR spectra for free 2,6-
diaminopyridine with [C2|H43NiiNi2](C104)4 also evidences that condensation of 2,6-
diaminopyridine has occurred and confirmed the formation of the bis-macrocycle. The 'H 
NMR spectrum of the free 2,6-diaminopyridine displays primary amine proton signals at 
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5.29 and 5.59-5.61 ppm which disappear in [C2iH43NiiNi2](C104)4 with simultaneous 
emergence of a new prominent peak at 2.58 ppm corresponding to the -CH2-N-CH2-
linkage protons [264]. A series of non-overl^ping multiplets in the high field region at 
3.12-3.88 ppm and 4.86 ppm were attributed to the -(CH2)2-NH-(CH2)2-NH- chain of the 
macrocyclic framework [265,266]. 
The '^C NMR spectrum reveals signals in the region 32.6-39.04, 45.58-48.77 and 51.31-
55.73 ppm representing - CH2- carbons of macrocyclic backbone [267]. Peaks at 134.23 
and 120.12 ppm appear due to the aromatic ring carbons. This pattern of '^ C NMR 
resonances was consistent with ' H NMR data and agrees well with the proposed bis -
architecture of the complexes (Table 12). 
Mass spectroscopy 
ESI MS mass spectroscopy provides the key evidence for the formation of the 
macrocyclic complexes. The ESI MS spectrum of the [C2iH43NiiNi2](C104)4 complex 
shows peaks at m/z 868, 385, 223 and 141 corresponding to the molecular ions of the 
formulations [M-C104' + SH't, [M-2C104- + 2ltf^, [M-3C104' + H^]^^ and [M-
4CIO4' ] ^ ^ respectively, resulting from the stepwise loss of the perchlorate anions (Table 
13). The mass spectrum also shows some prominent peaks representing successive 
fragments of the complex molecule. The appearance of peaks at m/z 522, 161, 121, 305 
and 100 are ascribed to the species [Ci3H23N5Cl208Ni], [Ci3H23N5Cl208Ni - 2CIO4" f^, 
[C8H2oN5Cl208Ni - 2 C 1 0 4 ] ^ [C6H,6N4Cl208Ni - C104] '^ and [C6H,6N4Cl208Ni -
2C104"]^^ respectively. The peaks occurring at m/z 149 and 77 corresponding to 1,8-
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diamino-3,6-diazaoctane and pyridine group, respectively, further confirm this 
Segmentation pattern. 
Electronic absorption Spectra 
The UVA^is absorption spectra of [C2iH43NiiCo2](C104)4, [C2iH43NiiNi2](C104)4 and 
[C2iH43NiiCu2](C104)4 complexes (1x10'^ M) were recorded at 25 °C in H2O. In the UV 
region the complexes display two main transitions i) an intense band at 325-340 nm, 
attributed to LMCT transitions and ii) a strong band at 230-250 nm ascribed to 
intraligand charge transfer transitions [268]. The visible absorption spectra of complex 
[C2iH43NiiCo2](C104)4 was characterized by an absorption band at 425 nm due to the 
metal d-d electronic transition attributed to 'Aig • 'Big transition [269] consistent with 
a square planar geometry around the cobalt metal ion. Similarly, complex 
[C2iH43NiiNi2](C104)4 displayed a shoulder at 415 nm [229] assigned to the 'Aig—• 'A2g 
transition of low spin Ni(II) in a square planar environment. Complex 
[C2iH43NiiCu2](C104)4 shows a distinct absorption band at 585 nm due to ligand field d-d 
transitions assigned to Big—• A2g transitions, again in agreement with the square planar 
geometry of Cu(II) ion [270]. 
EPR spectral studies 
The solid state X-band EPR spectra of the complex [C2iH43NiiCu2](C104)4 was acquired 
at a frequency of 9.1 GHz under the magnetic field strength 3,000±1,000 guass using 
tetracyanoethylene (TCNE) as field marker at LNT. The complex shows an anisotropic 
spectrum with gy = 2.049 and gi = 2.01 and gav = 2.02 computed fi-om the expression gav^  
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= (g|| ^  + 2gi^)/3. These parameters are in good agreement to the values reported for other 
related square planar Cu(II) systems [271] and are typical of axially synmietrical d' 
Cu(II) complexes. The trend gn > gj. > 2 reveals that the unpaired electron is present in 
the dx^ -y^  orbital [272]. For a Cu(II) complex, g\\ is a parameter sensitive enough to 
indicate covalence. For a covalent complex, g|| < 2.3 and for an ionic environment, g\\ = 
2.3 or more. In the present complex gn < 2.3 indicates an appreciable metal-ligand 
covalent character [273]. The G factor defined as G = (gy - 2)/(gi- 2) indicative of 
exchange interactions between the Cu(n) sites equal to four suggests negligible exchange 
interactions. 
Biophysical studies with CT DNA and 5'G]VIP 
DNA binding is the critical step for many cytotoxic compounds as it is the primary 
pharmacological target of antitumor drugs. Metal complexes are particularly attractive 
systems to study as the ligating organic molecules are held firmly in place by the metal 
ions, giving specific shape and surface features to the complex that can be exploited to 
affect the DNA-metallocomplex interaction. The mode and propensity of binding of 
[C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4 complexes to CT DNA has been 
evaluated by the absorption titration, luminescence titration, cyclic voltammetry and 
viscosity measurements. 
Absorption titration 
The potential CT DNA binding ability of complexes [C2iH43NiiCo2](C104)4 and 
[C2iH43NiiCu2](C104)4 were studied by UVA^is spectroscopy by following the intensity 
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changes of the intraligand transition bands. Figure 50a-b displays the absorption spectra 
of [C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4 in the absence and presence of CT 
DNA respectively. On addition of CT DNA to the aqueous solution of 
[C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4 there is an incremental increase in 
absorbance of IL transitions. A moderate bathochromic shift (4-5 nm) in UV region was 
also observed for [C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4. Hyperchromicity 
with bathochromic shift is a feature of DNA binding mode either through covalent 
coordinate linkage to N7 nucleobase of DNA [116, 274] or electrostatic interaction to the 
major/minor groove of DNA helix [275]. 
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Figure 50a. UV spectral traces of [C2iH43N,,Co2j(Cl04)4 complex in Tris-HCl buffer 
(0.01 M, pH 7.2) upon addition ofCTDNA. Inset: Plots of [DNA]/ Ea-Sf versus [DNA]; 
(m), experimental data points; full lines, linear fitting of the data, [complex] = 6.6 x 10'^ 
M. 
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Figure 50b. UV spectral traces of [C2iH43NnCuJ(€104)4 complex in Tris HCl buffer 
(O.OIM, pH 7.2) upon addition ofCTDNA. Inset: Plots of [DNAJ/ Ca-e/versus [DNAJ; 
(m), experimental data points; full lines, linear fitting of the data; [complex] = 6.6 x ICF^ 
M. 
There is every possibility for both binding modes due to the molecular structure of the 
complexes-strong Lewis acid metal centres separated at an optimum distance, which 
favours coordination to the N7 of guanine nucleobase while electrostatic interaction 
could be due to interaction of positively charged metal ions with negatively charged 
oxygens of the phosphate backbone of the DNA helix. Since no significant changes were 
observed in the LF bands covalent/coordinate linkage to the N7 of nucleobase is strongly 
ruled out. This is also evidenced by the absorption titration with 5'GMP. Intercalation 
which leads to hypochromic spectral feature [276] is again ruled out in complexes 
[C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C 104)4. Therefore it is reasonable to assume 
that the complexes bind electrostatically to DNA. The cationic core of 
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[C2iH43NiiCo2](CI04)4 and [C2iH43NiiCu2](C104)4 could exert an enhanced electrostatic 
attraction due to an increase in the positive charge by the incorporation of more than one 
metal centers in a single molecule [277]. The higher the positive charge a dinuclear 
species possesses, the more cellular uptake is observed [278]. This feature along with 
high binding affinity of [C2iH43NuCo2](C104)4 and [C2iH43NiiCu2](CI04)4 may facilitate 
access to DNA target in a tumor cell. Besides this, divalent cations can repel and displace 
other counterions, leading to strong attraction with the proximal phosphate groups. The 
result is DNA bending by electrostatic collapse around a divalent cation [279]. Such 
general affinity would induce structurally ill-defined DNA aggregates [280]. Recently 
Farrell et al. [281] have reported a phosphate backbone-binding mode for a polynuclear 
Platinum (II) complex that has planar arrays of hydrogen bond donors leading to 
association with the DNA phosphate backbone. It is obvious that the coordinated -NH-
groups of the present macrocyclic complexes may also sterically clash with the DNA 
surface and involve in the hydrogen bonding with the phosphate oxygens. Additionally 
hydrogen bonding, in which the -NH- of the ligand serves as a hydrogen bond donor 
would be expected to create partial negative charge on the ligand nitrogen atoms. This 
charge effect would make the ligand a better o-donor to the metal, rendering the 
coordination of metal ion to the nucleobase difficult. In order to compare quantitatively 
the binding strength the intrinsic binding constant Kb for [C2iH43NiiCo2](CI04)4 and 
[C2iH43N)iCu2](C104)4 were calculated to be 1.64x10* M"' and 2.05x10* M'' respectively. 
These values are significantly lower than typical intercalators (EthBr-DNA ~ 10^  M"'). 
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Interaction with 5' GMP 
To corroborate our results of UVA^is titrations with CT DNA, interaction studies of 
[C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](Cl04)4 with 5'GMP in double distilled water 
were carried out (Figure 51a-b). The interaction between the metal complex and 5'GMP 
is expected to perturb the ligand field transitions of the metal complex due to 
coordinate/covalent linkage either to N7 or 06 of guanine base [282]. However upon 
addition of 5'GMP, there is substantial increase in the absorption of IL bands in the UV 
region while small changes were observed at the absorption maxima due to LMCT bands. 
No shifts in the visible absorption bands were observed which implies that there is no 
change of the coordination environment of the metal ions [283]. Coordination to the N7 
and 06 positions of 5'GMP are thus ruled out, in view of the steric hindrance by the 
macrocyclic rings. These results reveal that the complexes interact with 5'GMP 
exclusively through hydrogen bonding of -NH- groups to base nitrogen atom or 
phosphate oxygen atom or by electrostatic interactions of the metal ions utilizing the 
phosphate oxygen atoms of the nucleotide. 
Fluorescence spectroscopic studies 
As the complexes [C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4 are non-emissive 
both in presence and absence of DNA, competitive DNA binding experiments with the 
proven DNA intercalator, ethidium bromide provided additional information about the 
DNA binding properties of the bis- macrocyclic complexes [C2iH43N|iCo2](C104)4 and 
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Figure 51a- UVspectral traces [C2iH4}NnCo2](004)4 complex in double distilled water 
upon the addition of 5 'GMP. 
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Figure 51b. UV spectral traces [C21H43N1 /CuJ (€104)4 complex in double distilled water 
upon the addition of 5 'GMP. 
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[C2iH43NiiCu2](C104)4. EthBr shows reduced fluorescence intensity in a buffer medium 
due to the quenching by solvent molecules and an increase in fluorescence intensity when 
bound to DNA, because of its strong intercalation between the DNA base pairs and 
stabilization of its excited state [284]. Addition of Complexes [C2iH43NiiCo2](C104)4 and 
[C2iH43NiiCu2](C104)4to EthBr-DNA system decreases the emission intensity at 590 nm 
indicating that complexes have a good affinity for DNA (Figure 52a-b). The extent of 
fluorescence quenching reflects the extent of binding of complexes to DNA [285]. Two 
mechanisms have been proposed to account for the quenching viz; the displacement of 
ethidium bromide from DNA and electron transfer from excited ethidium to an acceptor 
(e.g; cupric ion, Cu^ "^ ) [286]. As complex [C2iH43NiiCo2](C104)4 and 
[C2iH43N||Cu2](C104)4 bind to DNA via surface binding, displacement of strongly bound 
EthBr cannot take place. Instead the observed quenching is due to the facile 
intramolecular photoinduced electron transfer from the excited EthBr to complex bound 
to DNA [287]. The quenching extent by [C2]H43NiiCu2](CI04)4 is larger than 
[C2iH43N|iCo2](C104)4 This is expected, as the reduction of DNA-bound complex 
[C2iH43N,,Cu2](CI04)4 is easier than [C2iH43NnCo2](C104)4, (E° = ^ 4 5 mV and ^ 1 5 
mV for [C2iH43NiiCo2](C104)4and [C2iH43NiiCu2](CI04)4, respectively). Moreover, it is 
possible that the low energy ligand based TC* orbitals could facilitate the photoinduced 
electron transfer. 
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Figure 52a. Emission spectra of EthBr bound to CT DNA in the presence of 
[C2iH43NiiCo2](Cl04)4 and in Tris-HCl buffer. Inset: Plots ofljl vs [complex]/[DNA]; 
[DNA] = 3.3xia^M; X,^^ SlOnm. 
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Figure 52b. Emission spectra of EthBr bound to CT DNA in the presence of 
[C2iH43NiiO,6Cu2Cl4] and in Tris-HCl buffer. Inset: Plots of UI vs [complex]/[DNA]; 
[DNA] = 3.2xW^M; Xex= SlOnm. 
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The emission spectra of the EthBr-bound DNA in the absence and presence of complex 
[C2iH43NiiCo2](C104)4 and [C2iH43NnCu2](C104)4 alongwith the titration plots (inset) 
are given in Figure 52a-b. The plots depict that the quenching of EthBr bound to DNA by 
the metal complex is in good agreement with the linear Stem-Volmer equation, implying 
that the complex competes with EthBr in binding to DNA. 
In the plot of IQ/I VS r, the Stem-Volmer quenching constant K^ v is given by the ratio of 
the slope to the intercept. The Kgv value for the complex [C2iH43NnCo2](C104)4 and 
[C2iH43NiiCu2](C104)4 as estimated by using equation 2 were found to be 0.07 and 0.44 
respectively. 
Viscosity studies 
To explore further the mode of binding to DNA, the viscosity of the CT DNA solution 
were measured by varying the concentration of the added metal complexes. 
Hydrodynamic method, such as determination of viscosity, which is exquisitely sensitive 
to the change in length of DNA, is the most effective means for studying the binding 
mode of complexes to DNA in solution especially in absence of crystallographic data 
[288]. Electrostatic interactions typically cause less pronoimced or no change in the DNA 
solution viscosity, while partial intercalation induces static bends in DNA double helix, 
reducing its effective length and concomitantly its viscosity [126]. 
The variation of the relative specific viscosity with addition of the increasing 
concentration of the complex [C2iH43NiiCo2](C104)4 and [C2iH43NiiCu2](C104)4 is given 
in the Figure 53a-b. The viscosity of DNA decreases steadily with increasing 
127 
concentration of the metal complex, indicating that the DNA becomes more compact 
because of its interaction with metal complex. These experimental results support the 
idea that the complex [C2iH43NuCo2](C104)4 and [C2iH43NuCu2](C104)4 bind to DNA 
by simple electrostatic interactions. In addition to this hydrogen bonding interactions of 
the coordinated -NH- groups with the base pairs leads to the bending of the DNA chain 
resulting decrease in the DNA viscosity [221]. These observations are consistent with the 
results from UVA^is and luminescence titrations. 
Cyclic Voltammetry 
Cyclic Voltammetry is employed to study the interaction of metal complexes with DNA 
owing to the resemblance between electrochemical and biological reactions. Based on the 
shift of the formal potentials in the cyclic voltammograms, the relative binding affinities 
and binding modes of the metal complexes with DNA can be deduced. The redox 
behavior of the bis-macrocyclic complex [C2iH43NiiCo2](C104)4 and 
[C2iH43NiiCu2](C104)4 in absence and presence of CT DNA has been studied by means 
of cyclic voltammetry in H2O/DMSO (95:5) over a sweep range of 1.6 to -0.8 V at a scan 
rate of 0.3 VS' . The CV of bis-macrocyclic complex [C2iH43NiiCo2](C104)4 (Figure 54) 
in the absence of CT DNA features a non-Nemstian one quasi-reversible redox wave at 
cathodic peak potential Epc of -0.430 V and and anodic peak potential of -0.401 V, 
attributed to the Co(Il)/(I) couple. The formal electrode potential E1/2 estimated as the 
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Figure 53a. Effect of increasing amount of [C2iH4iNuCo2] (004)4 complex on the 
relative viscosity ofCTDNA at 29 ±0.1 "C. [DNA] =4x1 a'M. 
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Figure 53b. Effect of increasing amount of [C21H43N11CU2](004)4 complex on the 
relative viscosity ofCTDNA at 29 ±0.1 "C. [DNA] =4xia^M. 
129 
average of the anodic and cathodic peak potentials is -0.415 V (-415mV). The ratio of 
anodic and cathodic peak currents, Ipa/Ipc ~0.5 and AEp =0.30 V (30 mV) (Nemstian value 
= 59 mV) imply a one electron transfer process of Co(II)/Co(I). The voltammograms 
obtained at various scan rates does not show any marked change. In presence of CT DNA 
at the same concentration of metal complex, there is a considerable shift in the formal 
potential E1/2 = -0.445 V. The cathodic peak potential shifts to negative side (-0.490 V), 
while the anodic peak potential shifts to the positive side (-0.400 V). The ratio Ipa/Ipc 
decreases (0.43) for the CT DNA bound complex [C2iH43NiiCo2](C104)4 suggesting that 
the complex binds strongly to CT DNA by electrostatic association [289]. Cyclic 
Voltammogram of the complex [C2iH43N|iCu2](C104)4 (Figure 55) shows a well-defined 
redox process corresponding to the formation of the Cu(II)/Cu(I) couple with formal 
Figure 54. Cyclic voltammograms at a scan rate 0.2 Vs'' in H2O; curve a 
[C2iH43NnCo2](€104)4 complex alone; curve b [C21H43N11C02](004)4 complex in 
presence ofCTDNA. 
130 
Figure 55. Cyclic voltammograms at a scan rate 0.2 Vs'' in H2O; curve a 
[C2iH43NiiCu2j(Cl04)4 complex alone; curve b [C2iH43NiiCu2](Cl0^4 complex in 
presence ofCTDNA. 
potential E1/2 = -0.375 V. The couple is found to be quasi-reversible with AEp =70 mV 
and the ratio of the anodic to cathodic peak currents (Ipa/Ipc = 0.23) correspond to the 
simple one electron process. The large peak width for the one electron couple 
Cu(II)/Cu(I) indicates the structural reorganization of the coordination sphere during the 
electron transfer [290]. Upon the addition of CT DNA the formal electrode potential E° 
value (-0.415 V) shifts towards more negative side. 
The apparent reduction in peak currents of [C2iH43N|iCo2](C104)4 and 
[C2iH43NiiCu2](C104)4 upon the addition of CT DNA is attributed to the diffusion of the 
complexes bound to large, slowly diffusing DNA molecules. These results are 
comparable with the behaviour of other reported mononuclear and their corresponding 
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polynuclear complexes [291]. The occurrence of a single redox wave implies that the two 
copper (II) centers in [C2iH43NiiCu2](C104)4 simultaneously exchange electrons with the 
electrode and that the coulumbic interactions between the metal centers are negligible 
[292]. Further the shifts in E\a to more negative values support the binding of the 
complexes to DNA surface with significant contributions from electrostatic forces of 
attraction [293]. 
o 
o U 
en 
o 
M 
ct 
'O 
^^ 
ct 
u 
•••* 
ct 
a 
ct 
'O 
a 
, , 
R 
V) b JS &H 
T t 
' ^ 
o 
u 
n 
9 
U 
»H 
;5 
<^ I S 
u 
R 
• * 
^ 
o 
u >^ ^ 
r< 
o\ 
T3 JJ 
U 
c s o 
2 
3 
o U 
X 
B 
o U 
O 
•^  
o^ 
u 
o 
<N 
00 
<n 
'"' 
OS 
Tt 
CN 
m 
vo <N 
VO 
0\ 
v^ 
^ 
ON 
S 
.^^  
CN 
T - ^ 
O 
r< 
,_ 
<N 
VO 
ON 
• * 
(N 
(N 
VO (N 
^ 
ON 
u-i 
>*-• 
2^  
/—s 
• * 
^ 
vo (N 
<N 
r-
u-i 
OS (N 
«o 
O 
oo 
<n 
s_^ 
f 
2;^  
00 
00 
rsi 
vo 
4= 
'•B 
-a u 
o 
(N 
<N 
c<^  
r«^  
t^ 
o CO 
vo 
c 
2 
•I 
Q 
o 
o 
vo 
I 
o 
ON 
132 
d 
u 
CN 
O 
u 
z f»l 
:£ 
<N 
u 
d 
u 
Z 
z 
:S 
<N 
u 
o 
u 
n 3 
u 
z m 
a? 
fS 
u 
S 
O 
U 
I o 00 • * «n o w^  
133 
c 
o 
en 
o 
00 
o O 
o o 
00 
>r> 
o 
w-1 
fN 
VO 
• ^ 
o 
U 
(3 u 
p 
00 o 
vo 
PC 
u 
00 
ON 
VO 
r~ tN 
u-> 
r^  
r^  tN 
o 
4i 
oi O 
h-i s 
U 
r~ 
•* (N 
rr^ 
O 
»r> {N 
en 
o 
o 
<N 
CT) 
X 
u 
"E, 
B 
o U 
O 
U 
IN 
o q 
u 
d 
u 
d 
3 
134 
a 
a 
"a 
a 
o 
U 
H 
u 
I 
U 
U 
U 
I 
o O 
0 0 
oo 
00 
rn 
I 
0 0 
U 
CM 
u 
a a a 
^^ 
"a 
a 
o 
O 
U 
H 
X 
^ 
OH 
1 
CM 
X 
u ts 
ffi 
u 1 
1 
u 
z 1 
«N 
K U 
1 
>< 
u t 
o U 
CN 
'—' C> 
<N 
^ 
• ^ 
r'l 
m t^ 
r-; r-; 
>o oo' 
>r> T t 
^H 00 
ro U-) 
^ vS 
>r> Tf 
O 
0 \ 
1 
^ (N 
r<^ 
• « • 
r—V 
• • 
o 
u s_x 
C4 
>-• 
z CO 
^ 
ts 
u b i . » J 
135 
• 
N 1 
9i 
a 
o u 
•V 
o mm 
u 
* P 4 
Z 
w^ v H 
M 
u 
<4-l 
o 
et 
mm 
03 
U 
V 
a 
«« 03 
s 
c« s 
^ o ^ 
• 
1-H 
V 
2 C4 
H 
+ 
o 
u t 
S 
+ 
p — 1 
tc 
+ 
d 
u 
c^ 
s 
+ 
S' 
+ 
d 
o 
1 
+ r—1 
+ 
, d 
u 1 
2 U—J 
t 
o U 
^ 
• * 
r4 
0 0 
0 0 
0 0 
• < l -
* 
o U 
^ 
<N 
U^ 
CHAPTER VI 
Cytotoxic Activity of a Potent Coumarin ligand 3-acetoacetyI-7-methyi-
pyrano-(4,3-b)-pyran-2,5-dione against Different Cell Lines: Design of 
Metal based Chemotherapeutic Agents derived from this Ligand and 
their DNA Binding ProHIe 
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CHAPTER VI 
Experimental 
Reagent grade chemicals were used without further purification for all syntheses. 
Co(C104)2.6H20, Ni(C104)2.6H20, Cu(C104)2.6H20 and Zn(C104)2.6H20. rac-1,2-
diaminocyclohexane, triethylorthoformate, 4-hydroxy-6-methyl-2H-pyran-2-one (Fluka) 
and Tris-base (Merck) were used as received. Calf thymus DNA (CT DNA) was obtained 
from Sigma. 6X loading dye and supercoiled pBR322 plasmid DNA were procured from 
Fermental Life Science and Genei respectively. Microanalysis (%CHN) was performed 
on a Perkin Elmer elemental analyzer model 2400. Molar conductances were measured at 
room temperature with a Eutech Instruments CON 510 digital conductometer. Infrared 
spectra were collected by using KBr pellets on a Perkin Elmer spectrum RX-1 FT-IR 
spectrometer. ' H and '^ C spectra were recorded on a Bruker Avance-II spectrometer at 
400 MHz and 100 MHz respectively. Chemical shifts were reported on the 5 scale in 
parts per million (ppm). The EPR spectrum of the copper complex was acquired on a 
Varian E 112 spectrometer using X-band frequency (9.1GHz) at liquid nitrogen 
temperature in solid state. The electrospray mass spectra were recorded on a Micromass 
Quattro II triple quadrupol mass spectrometer. Emission spectra were recorded with a 
Hitachi F-2500 fluorescence spectrophotometer. 
All the experiments involving the interaction of the complexes with DNA were 
conducted in aerated Tris-HCI buffer (0.0 IM, pH 7.2). 
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The cleavage of supercoiled pBR322 plasmid DNA in absence of activating agents was 
observed using gel electrophoresis. In reactions using supercoiled pBR322 plasmid DNA 
(300 ng) in Tris-HCI (10 mmol) buffer at pH 7.4 was treated with complex 
C38H44N4O18CI2CU (50-250 ^mol). The samples were incubated for 1 h at 37° C. A 
loading buffer containing 25% bromophenol blue, 0.25% xylene cyanol, 30% glycerol 
was added and electrophoresis was carried out at 100 V for 2 h in Tris-HCI buffer using 
1% agarose gel containing 1.0 ^g/mL ethidium bromide. The DNA cleavage with added 
reductant ascorbic acid was monitored as in case of cleavage experiment without added 
reductant using agarose gel electrophoresis. Reactions using supercoiled pBR322 plasmid 
DNA in Tris-HCI buffer at pH 7.4 was treated with complex C38H44N4O18CI2CU (50-250 
^mol) and ascorbic acid (10 jimol). The samples were incubated for 1 h at 37 °C. All the 
gels were viewed by UVP gel doc system and photographed. 
The anticancer activities against different human cancer cell lines were carried out using 
SRB assay. The human tumour cell lines of the cancer-screening panel were grown in 
RPMI-1640 medium containing 5% foetal bovine serum and 2 mM L-glutamine. For a 
typical screening experiment, cells were inoculated into 96-well microtitre plates in 100 
^L at plating densities ranging from 5000 to 40,000 cells per well depending on the 
doubling time of individual cell lines. After cell inoculation, the microtitre plates were 
incubated at 37 °C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to 
addition of ligand C13H10O6. Following compound addition, the plates were incubated for 
an additional 48 h at 37 °C, 5% CO2, 95% air and 100% relative humidity. For adherent 
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cells, the assay was terminated by the addition of cold trichloroacetic acid. 
Sulforhodamine B solution (100 ^L) at 0.4% (w/v) in 1% acetic acid was added to each 
well, and plates were incubated for 10 min at room temperature. After staining, unbound 
dye was removed by washing five times with 1% acetic acid and the plates were air-
dried. Bound stain was subsequently solublized with 10 mM trizma base, and the 
absorbance was read on an automated plate reader. The growth inhibitory rate of treated 
cells was calculated by (ODcontroi - ODtestVODcontroi x 100%. 
Synthesis of [3-acetoacetyI-7-inethyl-pyrano-(4,3-b)-pyran-2,5-dione] CnHioOg 
The ligand was synthesized by a procedure as follows [294]. 
4-hydroxy-6-methyl-2H-pyran-2-one (0.01 mol, 1.00 g) was added in portions to a 
preheated mixture of moist ethylorthoformate (0.01 mol, 1.66 mL) containing traces of p-
toluene sulphonic acid. The reaction mixture was heated for 15 minutes and cooled to 10 
C when an orange coloured crystalline solid precipitated. It was recrystallized from 
chloroform. 
General Procedure for the synthesis of macrocyclic complexes 
C38H44N40,8Cl2Co, C38H44N40i8Cl2Ni, C38H44N40,8Cl2Cu and C38H44N40l8Cl2Zn 
To a solution of an appropriate metal perchlorate (5.00 mmol) in 20 mL of methanol, 
1.22 mL (10.00 mmol) of rac-l,2-diaminocyclohexane was added dropwise. The reaction 
mixture was stirred at 35 °C for 30 minutes and then 2.62 g (10.00 mmol) of ligand 
C13H10O6 dissolved in 30 mL of methanol was added, stirred for additional 1 h and heated 
under reflux for 6 h until peculiar colour changes were observed. The reaction mixture 
139 
was filtered and the filtrate was evaporated under vacuum to remove the solvent. The 
product obtained was purified by repeated recrystallazation from MeOH/CHCb and air-
dried. 
Results and discussion 
The complexes having a general formula [ML2(dach)2(H20)2](C104)2 where M = Co(II), 
Ni(II), Cu(II) and Zn(II) and L = 3-acetoacetyl-7-methyl-pyrano-(4,3-b)-pyran-2,5-dione 
and dach = diaminocyclohexane were prepared in situ by mixing a methanolic solution of 
metal perchlorates to the solution of diaminocyclohexane and the 3-acetoacetyl-7-methyl-
pyrano-(4,3-b)-pyran-2,5-dione ligand on reflux in 1:2:2 molar ratio (Scheme 4). The 
ligand was synthesized by the method described earlier [294] by the reaction of 4-
hydroxy-6-methyl-2H-pyran-2-one with preheated mixture of moist ethylorthoformate 
with traces of PTS. The reaction mixture yielded yellow crystalline solid on heating for 
15 minutes and cooling at 10 °C. The ligand was recrystallized from a mixture of 
chloroform. The complexes [ML2(dach)2(H20)2](C104)2 were also recrystallized from 
chloroform/methanol mixture and pure complexes were obtained by separating the 
compound by preparatory TLC (CHCI3/CH3OH, 95:5). The yield of the complexes was < 
50%. The complexes were air stable and insoluble in water, sparingly soluble in MeOH, 
good soluble in DMSO, DMF and CHCI3. Molar conductance measurements showed that 
complexes are ionic in nature. The formation of complexes was ascertained by elemental 
analysis, which serves as a basis for the determination of their empirical formulae, 
confirmed by IR spectroscopy, 'H , '^C N M R spectroscopy and mass spectral data. All 
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these spectroscopic data supported the presented formulae and the proposed structure of 
the complexes. The important properties and physical data of the complexes are given in 
Table 14. 
II n* II / ^ M ( C I O 4 ) 2 . 6 H j 0 /-V^> i '^^^-r-^ ° 
HjC'^^'^^O^O H,N NH, I HN ,N 
' CH3 
where M =Co(II), Ni(Il), Cu(n) and Zn(II) 
Scheme 4 
IR spectroscopy 
IR spectra of the ligand CuHioOe and the complexes [ML2(dach)2(H20)2](C104)2 were 
recorded in solid state as KBr discs in the range 500-3800 cm'". The ligand CnHioOe 
exhibits the characteristic stretching vibrations of the carbonyl groups of lactone rings at 
1760 cm' and 1724 cm"' and low frequency sharp band observed at 1626 cm"' was 
assigned to stretching vibration of the v(C=0) of the P-diketonate residue, which was in 
resonance with the lactone ring [295-297]. A broad band at 3431 cm"' characteristic of 
v(OH) vibration was attributed to the enolic OH vibrations implying that the ligand 
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exhibits keto-enol tautomerisation [298,299]. This was confirmed by the presence of a 
vinylic v(=CH) stretch at 3073 cm"'. Other medium intensity bands in the range 1300-
1400 cm"' due to the in plane bending modes of v(CH3) and v(=CH) groups were also 
observed. Absorption maxima found at 1554 cm' and 1197 cm"' were attributed to the -
v(C=C) and v(C-O) stretching modes of the pyran rings, respectively. The IR spectra of 
the macrocyclic complexes [ML2(dach)2(H20)2](C104)2 revealed some notable features. 
Disappearance of v(C=0) at 1724 cm"' and 1626 cm"' and the appearance of a strong 
band in the range 1641-1653 cm"' assigned to v(C=N) provided strong evidence for the 
conversion of ketonic groups into the azomethine groups of the Schiff base residues 
[300]. The macrocycle formation through Schiff base condensation was supported by the 
appearance of new bands in the range 2920-2935 cm' and 2857-2861 cm"' due to 
symmetric and asymmetric v(CH2) vibrations of the dach moieties. Additionally the IR 
spectra of the complexes also display a wide band at 3329-3487 cm"' associated with the 
stretching vibrations of the water molecules and the coordinated v(NH) groups. This 
substantiates the fact that both the ligand and the metal complexes show tautomerism. 
However, bands belonging to v(OH) bending vibrations could not be assigned, owing to 
the overlay with very intense v(C=N). The conclusive evidence for the coordination mode 
of metal complexes was deduced by the observation of new v(M-N) bands around 513-
527 cm' in the far IR region [301,302]. Similarly, the presence of uncoordinated 
perchlorate anions was depicted by the lack of splitting of v(Cl-O) bands observed in the 
range 1055-1114 cm"' and 624-649 cm"' [303] (Table 15). 
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NMR Spectra 
The identification of ligand CisHjoOe and the metal complexes was further obtained from 
NMR spectroscopy. The ' H NMR spectrum of the ligand C13H10O6 displayed a broad 
signal at 15.75 ppm, characteristic of enolic proton [304]. Peaks with chemical shifts near 
6.25-8.76 ppm were ascribed to -C=CH and -CH=C-C ring protons. The signals for the 
alkyl -CH3 protons and the vinylic =CH protons were detected at 2.09-2.31 ppm, 2.41-
2.45 ppm and 4.09-4.12 ppm. Similar chemical shifts were observed for the 
corresponding protons in ' H NMR spectrum of the complex C38H44N40i8Cl2Zn. The -
OH resonance disappears while a new peak at 5.61-5.70 ppm emerges due to the 
coordinated -NH proton. Additional peaks in the range 1.88-1.92 and 1.96-2.18 ppm 
absent in the spectrum of the ligand CnHioOe were attributed to different cyclohexyl ring 
protons (Table 16). 
The '^ C NMR spectra of the ligand CnHioOe and the complex C38H44N40i8Cl2Zn 
corroborated well with the proposed structures. In the spectrum of CuHioOe, the '^ C 
NMR signals for the two lactonic carbonyl carbons appear at 156.13 and 159.31 ppm 
[305]. Resonances due to -C=0 and =CH-OH of the diketone residue appear at 199 ppm 
and 168 ppm, respectively [306]. However, significant changes were observed in the 
spectrum of complexes C38H44N40i8Cl2Zn. A new signal appeared at 175.33 ppm due to 
C=N, confirming the cyclization of the ligand with the dach moieties. Resonances at 
20.09 and 24.38-28.94 were ascribed to the cyclohexyl ring carbons and the CH3 groups. 
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respectively. Other peaks remained almost undisturbed in the spectrum of the complex 
C38H44N40i8Cl2Zn (Table 17). 
Electronic spectra 
The electronic spectrum of the ligand CuHioOe in CHCI3 show intense absorption bands 
at 220 nm, 279 nm and 437 nm. The strong bands appearing at the low energy side were 
assigned to n-+ TC* associated with the C=0 group. The bands at the higher energy arise 
from 7t-* 7t* transitions within the lactonic rings or exocyclic carbonyl groups [307]. 
These absorption bands in complexes C38H44N4O18CI2C0, C38H44N40i8Cl2Ni, 
C38H44N4O18CI2CU and C38H44N40i8Cl2Zn are shifted to longer wavenumbers compared 
to those of ligands. A prominent band at 309-350 nm was ascribed to n —* 7t* transition of 
the azomethine chromophore [308]. In the visible region, complexes C38H44N4O18CI2C0, 
C38H44N40i8Cl2Ni and C38H44N4O18CI2CU revealed bands at 520 nm, 670 nm and 588 nm 
ascribed to d-d transitions of the Co(II), Ni(II) and Cu(II) ions, respectively in an 
octahedral coordination geometry [309-311]. 
Mass spectroscopy 
Electrospray ionization mass spectra of the ligand CnHioOg and the metal complexes 
C38H44N4O18CI2C0, C38H44N40i8Cl2Ni, C38H44N4O18CI2CU and C38H44N40i8Cl2Zn were 
obtained to confirm their proposed molecular formulae. The ligand C13H10O6 displayed 
the molecular ion peak at m/z 262.3. The mass spectra of complexes C38H44N4O18CI2C0, 
C38H44N40i8Cl2Ni, C38H44N4O18CI2CU and C38H44N40i8Cl2Zn recorded molecular ion 
peaks at m/z 973.7, 973.0, 979.0, 981.1 respectively. Fragments obtained by the 
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successive expulsion of the coordinated water molecules were also depicted in the mass 
spectra of the complexes C38H44N4O18CI2C0, C38H44N40i8Cl2Ni, C38H44N4O18CI2CU and 
C38H44N40i8Cl2Zn, supporting the proposed molecular formulae (Table 18). 
EPR spectrum 
Solid state X-band EPR spectrum of the C38H44N4O18CI2CU complex obtained at LNT at 
9.1 GHz, recorded an isotropic signal at 2.04 with the unpaired electron located in dz 
orbital having an octahedral geometry [312]. 
In vitro DNA binding studies 
Absorption titration witli CT DNA 
Electronic absorption spectroscopy is one of the most useful techniques for DNA binding 
studies of metal complexes. Absorption spectral titrations were performed by maintaining 
a constant concentration of the ligand CuHioOe (0.066.10'^ M) and the complex 
C38H44N4O18CI2CU (0.016.10"^ M) and varying the nucleic acid concentration (0.120.10'^ 
M - 0.301.10-' M for ligand CnHioOe and O.OSS.IO"^  M - 0.277.10-^ M complex 
C38H44N4O18CI2CU. The absorption spectra of the ligand CnHioOe and complex 
C38H40N4O16CI2CU in the absence or presence of CT DNA are given in Figure 56. The 
ligand exhibits the absorption maxima at 279 nm and 437 nm attributed to n-*n* and 
n—*n* transitions respectively. In presence of CT DNA, both the absorption bands 
exhibited hyperchromism and the band at 279 nm also undergoes a red shift of 5 nm. The 
hyperchromicity implies that some interaction other than intercalation has occurred 
between ligand and DNA, because intercalation would lead to hypochromism and 
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bathochromic shift in UV absorption spectra [313]. The intrinsic binding constant Kb for 
ligand to CT DNA was calculated to be 3.2.10^ M"', a value lower than those obtained for 
typical intercalators (EB-DNA ~10^). It appears that the hyperchromism occurs due to the 
aggregation of the planar ligand molecules on the DNA surface and/or intimate surface 
binding of the lactone rings along the DNA backbone [314]. The complex 
C38H44N4O18CI2CU exhibits three intraligand transitions at 215 nm, 279 nm and 309 nm 
attributed to 7t—»7t* and n ^ n* transitions, respectively and a d-d transition maximum at 
588 nm. In presence of CT DNA, interesting changes in absorption spectra were 
observed. Unlike the ligand C13H10O6, the complex exhibited hypochromism at 309 nm 
absorption band attributed to n—» n*, while as the d-d transition at 588 nm undergoes 
hyperchromism with no red shift (Figure 57, 58). 
Mavelength (nir.) 
Figure 56. Absorption spectral traces of CuH/oOc ligand in Tris HCl buffer upon 
addition ofCTDNA. Arrow shows the absorbance change upon increasing concentration 
of the CT DNA. Inset: Plots of [DNA]/ Ea-Sf vs [DNA] for the titration of CnHwOe 
ligand with CT DNA; (m) experimental data points; full lines, linear fitting of the data. 
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This pattern reveals that while the UV absorption band undergoes hypochromism 
suggesting that the complex has intimate association with CT DNA and binds to the helix 
via partial intercalation [315, 316], at the same time electrostatic interaction due to the 
presence of strong Lewis acid copper centre of the complex to the negatively charged 
phosphate of the DNA helix probability increases which is clearly implied by 
hyperchromism of d-d absorption maxima [274,317]. The observed hypo and 
hyperchromic effects reveal that the complex C38H44N4O18CI2CU possesses more than one 
DNA binding mode. A good quality data was not obtained from titrations at metal d-d 
bands, making the determination of intrinsic binding constant inaccurate. Hence, binding 
constant was calculated at the intraligand band and was found to be 2.18. I O ^ M ' . 
Figure 57. Absorption spectral traces ofCi8H44N40i^l^u complex in Tris-HCl buffer 
upon addition of CT DNA Inset: Plots of [DNA]/ Sa-Sf vs [DNA] for the titration of 
C3SH44N4O18CI2CU complex with CT DNA; (u) experimental data points; full lines, linear 
fitting of the data. Arrow shows the absorbance change upon increasing concentration of 
the CT DNA. 
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Figure 58. Absorption spectral traces ofC38H44N40isCl^u complex in Tris-HCl buffer 
upon addition ofCTDNA at d-d absorption band. Arrow shows the absorbance change 
upon increasing concentration of the CTDNA. 
Absorption titration with 5'GMP 
To identify the specific binding site of the metal complex C38H44N40igCl2Cu to DNA, 
interaction studies with the nucleotide 5'GMP were examined by absorption titrations. 
On increasing the concentration of the nucleotide there was a sharp increase in intensity 
of the UV absorption band as shown in Figure 59. No significant changes were observed 
at the d-d absorption maxima. Therefore, coordination towards the N7 atom of guanine of 
the copper complex has been precluded. Hyperchromism at the UV absorption bands thus 
implies that the complex binds to DNA non-covalently, most probably through 
electrostatic interaction or by partial intercalation. 
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Wavelength (nm) 
Figure 59. Absorption spectral traces of C38H44N4O18CI2CU complex in Tris-HCl buffer 
upon addition of 5'GMP Arrows show the absorbance changes upon increasing 
concentration of the 5 'GMP. 
'H and '^P NMR studies with 5'GMP 
The interaction of complex C38H44N4O18CI2CU with guanosine 5'monophosphate was 
evaluated by using ' H and ^'P NMR technique. The 'H NMR of 5'GMP in D2O solvent 
recorded the proton resonance of guanine H8 at 8.10 ppm and ribose Hl'-HS' at 3.8-5.8 
ppm respectively. For paramagnetic complexes, the chemical shift of proton adjacent to 
the metal centre will be perturbed resulting in line broadening. On interaction of complex 
C38H44N40igCl2Cu with 5'GMP the H8 signal of guanine does not alter significantly 
(8.12 ppm) (Figure 60a-b). At different time intervals the spectra remains unaltered, 
revealing the non-participation of N7 of guanine in covalent binding [318]. Furthermore, 
there is line broadening of H8 and Hr-H5' signals of ribose sugar which indicate the 
presence of paramagnetic Cu(II) center in the proximity of these protons. ^'P NMR of 
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5'GMP reveals a signal at 3.67 ppm. On interaction of complex C38H44N4O18CI2CU with 
5'GMP, there is upfield shift of 3.60 ppm (0.07 ppm) indicative of electrostatic binding 
mode of the complex C38H44N4O18CI2CU to the phosphate group of 5'GMP. Since there is 
no large upfield shift, it implies that the complex has weaker electrostatic tendency with 
the phosphate group and involves other non-covalent DNA binding mode. These 
observations were further corroborated by UV and fluorescence data. 
Fluorescence titrations 
The ligand C13H10O6 and the complex C38H44N4O18CI2CU emit luminescence in Tris-
buffer with a maximum appearing at 567 nm and 525 nm respectively. Upon the addition 
of increasing concentration of DNA (0.033.10"^M -0.166.10"^M), the emission intensity 
of both the ligand CnHioO^ and the complex C38H44N4O18CI2CU enhances gradually 
(Figure 61a-b). The emission enhancement is usually correlated with the extent to which 
the compounds penetrate into the hydrophobic pockets of DNA, thereby avoiding the 
quenching effects of solvent water molecules [319]. Due to the reduced solvent mobility 
at the binding site by the hydrophobic DNA macromolecule a decrease in vibrational 
modes of relaxation results and hence quenching efficiency, especially in case of 
intercalation [320, 321]. The emission titration results thus support the idea that both the 
ligand as well as the complex is protected from the solvent water molecules and can 
insert deeply into the DNA helix [322]. 
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Figure 60. 'H NMR spectra of (a) 5'GMP and (b) the reaction of C3sli44N40i^l2Cu 
complex (2.5 mM) with 5 'GMP (5 mM) in D2O at 25 "C. 
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To compare the binding affinity of the ligand and the complex C38H44N40igCl2Cu the 
binding data obtained from the emission spectra were fitted in the Scatchard equation to 
acquire the binding parameters. A plot of r/Cp vs r gave the binding constants 3.0 .10* M' 
'and 2.0 .lO'' M"' for the ligand CnHioOe and the complex C38H44N4O18CI2CU 
respectively. The calculated binding constants are different from those obtained by 
absorption titration due to the different spectroscopic and different calculation method. 
DNA Cleavage 
The interaction of the complex C38H44N4O18CI2CU with supercoiled pBR322 plasmid 
DNA was studied both in absence and presence of reductant, ascorbic acid employing gel 
electrophoresis. The binding of the complex with pBR322 plasmid DNA was determined 
by its ability to change its conformation from supercoiled (SC) to nicked open circular 
(NC) form. Different concentrations of complex C38H44N4O18CI2CU were mixed with the 
pBR322 plasmid DNA in Tris-HCI buffer in the absence and presence of the reductant 
ascorbic acid and mixtures were incubated at 37 °C for Ih. In the absence of ascorbic 
acid, pBR322 plasmid DNA was converted from SC (form I) to NC (form II). In presence 
of ascorbic acid at increasing concentration of the complex there was complete 
conversion of SC form I to nicked DNA form (II). The bands are more intensified in 
presence of ascorbic acid as depicted in Figure 62a-b. Control experiments using only 
complex or ascorbic acid failed to show any apparent cleavage activity. An oxidative 
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Figure 61. Emission enhancement spectra of (a) CnHioOe ligand and (b) 
C3SH44N4OisChCu complex in presence ofCT DNA in Tris-HCl buffer. Arrows show the 
intensity changes upon increasing concentration of the CT DNA C/jH/oOc and 
C3SH44N4O/SCI2CU (0.033.10' M); Inset: Scatchard plots of the fluorescence titration 
data; (m) experimental data points; full lines, linear fitting of the data. 
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cleavage mechanism has been proposed where Cu (II) is first reduced to the Cu (1) [323] 
by the ascorbic acid which then binds to DNA forming a Cu(I)complex-DNA adduct. 
NC 
sc 
NC 
- • SC 
Figure 62. Gel electrophoresis diagram showing cleavage of supercoiled pBR322 
plasmid DNA (300 ng) by CS8H44N4O18CI2CU complex, (a) in absence of ascorbic acid; 
250fiMC38H44N4O,8Cl2Cu + DNA, (lane 1), 200/uMC38H44N40,sCl2Cu + DNA (lane 2), 
I5OMMC38H44N4O/8CI2CU + DNA (lane 3), 100 ^M C38H44N4O/8CI2CU + DNA (lane 4) 
and 50 fiM C38H44N4O18CI2CU +DNA (lane 5), control DNA (lane 6); (b) in presence of 
ascorbic acid (10 ^M) 250 nM C38H44N4O18CI2CU + DNA, (lane 1), 200 fiM 
C38H44N4O18CI2CU + DNA (lane 2), 150 fiM C38H44N40,8Cl2Cu + DNA (lane 3), 100 nM 
C38H44N4O18CI2CU + DNA (lane 4) and 50 nM C38H44N40,8Cl2Cu +DNA (lane 5), 
control DNA (lane 6). 
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In Vitro Cytotoxicity 
The cytotoxic and/or the growth inhibitory effects of the ligand CnHioOe against the 
different human tumor cell lines derived from leukemia, non-small cell lung cancers, 
colon cancers; CNS cancer and melanoma were determined, using standard protocol for 
cell viability. The dose response curves (Figure 63) were evaluated and the optical data 
retrieved from logio concentration summarized in Table 19. 
The ligand CuHioOe exhibited inhibitory effect of almost same order with logio GI50 >-
4.43 for all cell lines except CNS cancer (SNB-75), which exhibited highest inhibition 
factor, logio GI50 = -5.56 at a concentration of 3.98 ^M. These experiments support that 
the compound exhibits a strong growth inhibitory effect selectively against CNS cancer 
SNB-75 cell line. 
Since chelation of metal ion with ligand enhances the inhibitory power of the compounds, 
therefore it is inferred that the complexes will possess greater cytotoxic effect than the 
free ligand itself 
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Figure 63. Dose response activity curves ofCijHioOe ligand against a) leukemia (b) 
Non-Small cell lung cancer (c) Colon cancer (d) CNS cancer (e) Melanoma cell lines. 
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Table 19.% Mean optical densities Growth Inhibition for selected cancer cell lines 
by CisHioOeligand 
Panel/ 
Cell Line 
Leukemia 
CCRF-CEM 
HL-60 (TB) 
K-562 
MOLT-4 
RPM1-8226 
SR 
Lung cancer 
A549/ATCC 
EKVX 
HOP-62 
NCI-H226 
NCI-H23 
NC1-H322M 
NCI-H460 
NCI-H522 
Colon Cancer 
COLO-205 
HCC-2998 
HCT-116 
HCT-15 
HT29 
KM12 
SW-620 
CNS Cancer 
SF-268 
SF-295 
SF-539 
SNB-19 
SNB-75 
U251 
Melanoma 
MALME3M 
M14 
SK-MEL-2 
SK-MEL-28 
SK-MEL-05 
UACC-257 
UACC-62 
Time 
Zero 
0.322 
0.273 
0.175 
0.420 
0.244 
0.421 
0.275 
0.697 
0.688 
1.213 
0.418 
0.502 
0.169 
0.408 
0.399 
0.473 
0.146 
0.121 
0.229 
0.375 
0.227 
0.474 
0.385 
0.481 
0.650 
0.489 
0.242 
0.642 
0.243 
0.479 
0.417 
0.306 
0.607 
0.335 
Ctrl 
1.083 
0.812 
1.108 
1.480 
0.546 
0.936 
1.205 
1.241 
1.972 
2.057 
1.448 
1.342 
1.356 
1.515 
2.296 
1.203 
1.125 
0.847 
0.983 
1.497 
1.252 
1.349 
0.692 
1.327 
1.891 
1.070 
1.180 
1.210 
1.046 
0.976 
0.912 
1.514 
1.604 
1.629 
Logio 
Mean Optical Densities 
-8.4 
0.946 
0.784 
1.194 
1.457 
0.502 
0.899 
1.194 
1.311 
2.018 
2.049 
1.487 
1.333 
1.311 
1.478 
2.300 
1.025 
1.064 
0.782 
0.977 
1.485 
1.291 
1.330 
0.639 
1.303 
1.934 
0.883 
0.970 
1.225 
0.988 
0.960 
0.928 
1.265 
1.552 
1.495 
-7.4 
0.923 
0.705 
1.054 
1.363 
0.508 
0.974 
1.215 
1.302 
2.047 
2.257 
1.503 
1.321 
1.371 
1.528 
2.506 
1.140 
1.075 
0.774 
0.968 
1.412 
1.194 
1.304 
0.632 
1.314 
1.920 
0.883 
0.965 
1.199 
0.978 
0.893 
0.930 
1.199 
1.594 
1.483 
-6.4 
0.961 
0.700 
0.931 
1.236 
0.448 
0.994 
1.130 
1.202 
1.999 
1.984 
1.396 
1.296 
1.155 
1.515 
2.222 
1.029 
0.992 
0.804 
0.929 
1.439 
1.172 
1.211 
0.609 
1.282 
1.854 
0.847 
0.850 
1.236 
0.963 
0.862 
0.945 
1.388 
1.483 
1.352 
concentration 
-5.4 
0.821 
0.648 
0.957 
1263 
0.450 
0.873 
1.125 
1.191 
1.946 
2.010 
1.531 
1.295 
1.221 
1.546 
2.204 
1.170 
1.058 
0.743 
0.950 
1.466 
1.104 
1.209 
0.595 
1.250 
1.858 
0.769 
0.895 
1.218 
0.969 
0.864 
1.046 
0.948 
1.474 
1.340 
-4.4 
1.023 
0.697 
1.067 
1.479 
0.530 
0.857 
1.067 
1.155 
1.974 
2.024 
1.583 
1.340 
1.084 
1.472 
2.105 
1.108 
0.990 
0.679 
0.854 
1.509 
1.293 
1.179 
0.558 
1.277 
1.811 
0.755 
1.144 
1.074 
0.961 
0.886 
0.919 
1.012 
1.424 
1.297 
-8.4 
82 
95 
109 
98 
86 
93 
99 
113 
104 
99 
104 
99 
96 
96 
99 
76 
94 
91 
99 
99 
104 
99 
83 
97 
104 
68 
76 
103 
93 
96 
103 
76 
93 
90 
Percent Growth 
-7.4 
79 
80 
94 
89 
88 
107 
101 
111 
106 
124 
105 
97 
101 
101 
111 
91 
95 
90 
98 
92 
94 
95 
81 
98 
102 
68 
77 
98 
92 
S3 
104 
74 
99 
89 
-6.4 
84 
79 
81 
77 
68 
111 
92 
93 
102 
91 
95 
95 
83 
100 
96 
76 
86 
94 
93 
95 
92 
84 
73 
95 
97 
62 
65 
105 
90 
77 
107 
90 
88 
79 
-5.4 
66 
70 
84 
80 
68 
88 
92 
91 
98 
94 
108 
94 
89 
103 
95 
95 
93 
86 
96 
97 
86 
84 
69 
91 
97 
48 
70 
101 
91 
78 
127 
53 
87 
78 
-4.4 
92 
79 
96 
100 
95 
85 
85 
84 
100 
96 
113 
100 
77 
96 
93 
87 
86 
77 
83 
101 
104 
81 
56 
94 
94 
46 
96 
76 
89 
82 
102 
58 
82 
74 
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